Document:

Exhibit 10.1   

Confidential treatment has been
requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*]. A complete
version of this exhibit has been filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

LICENSING AND
DISTRIBUTION AGREEMENT  

by and between  

BRADLEY
PHARMACEUTICALS, INC.  

and  

PAR PHARMACEUTICAL,
INC.  

* * *  

DOXYCYCLINE
MONOHYDRATE  

* * *  

DECEMBER 13, 2005  

 
	 	 
	 

TABLE OF CONTENTS  

	  	  	  	 Page
        

	 1.	 DEFINITIONS	 2
	  	  	  	  
	 2.	 LICENSE GRANT	 4
	  	 2.1	 License Grant	 4
	  	  	  	  
	 3.	 GENERIC PRODUCT DEVELOPMENT,
        MANUFACTURING AND DISTRIBUTION	 4
	  	 3.1	 Change of Tablet and Capsule Imprint	 4
	  	 3.2	 Appointment; Commercial Launch; Supply and
        Distribution	 4
	  	 3.3	 Packaging	 5
	  	  	  	  
	 4.	 FINANCIAL TERMS	 6
	  	 4.1	 Cost of Tablet and Capsule Imprint Change	 6
	  	 4.2	 Cost of Obsolete Inventory	 6
	  	 4.3	 Net Profit Split	 6
	  	 4.4	 Late Payments	 6
	  	 4.5	 Change in Circumstances	 7
	  	  	  	  
	 5.	 CERTAIN UNDERTAKINGS	 7
	  	 5.1	 Generic Product Complaints and Adverse Drug
        Experiences	 7
	  	 5.2	 Generic Product Recall	 7
	  	 5.3	 Facility Maintenance; Inspection; Reports	 8
	  	 5.4	 Filing Requirements and Maintenance	 9
	  	 5.5	 Insurance	 9
	  	 5.6	 Audit Right	 9
	  	 5.7	 Publicity	 9
	  	  	  	  
	 6.	 WARRANTIES; INDEMNIFICATION; AND
        LIMITATION OF LIABILITY	 10
	  	 6.1	 Certain Representations, Warranties and Covenants
        of Par	 10
	  	 6.2	 Certain Representations, Warranties and Covenants
        of Bradley	 11
	  	 6.3	 Representation and Warranties with Regard
        to Status	 11
	  	 6.4	 Par’s Indemnification Obligations	 11
	  	 6.5	 Bradley’s Indemnification Obligations	 12
	  	 6.6	 Indemnification Procedures	 12
	  	  	  	  
	 7.	 TERM AND TERMINATION	 13
	  	 7.1	 Term	 13
	  	 7.2	 Termination for Breach	 13
	  	 7.3	 Termination for Bankruptcy	 13
	  	 7.4	 Termination for Change in Circumstances	 13
	  	 7.5	 Post-Termination	 13
	  	  	  	  

 
	 	 
	 

TABLE OF CONTENTS 
(continued) 

	  	  	  	 Page
        

	 8.	 CONFIDENTIALITY	 14
	  	 8.1	 Treatment of Confidential Information	 14
	  	 8.2	 Limits on Disclosure	 14
	  	  	  	  
	 9.	 FORCE MAJEURE	 15
	  	 9.1	 Effects of Force Majeure	 15
	  	 9.2	 Notice of Force Majeure	 15
	  	  	  	  
	 10.	 MISCELLANEOUS	 15
	  	 10.1	 Dispute Resolution	 15
	  	 10.2	 Independent Contractors	 15
	  	 10.3	 Assignment	 16
	  	 10.4	 Governing Law; Waiver of Jury Trial	 16
	  	 10.5	 No Implied Waiver	 16
	  	 10.6	 Notice	 16
	  	 10.7	 Amendments	 17
	  	 10.8	 Counterparts	 17
	  	 10.9	 Interpretation	 17
	  	 10.10	 Entire Agreement	 17
	  	 10.11	 Benefit; Binding Effect	 18
	  	 10.12	 Survival	 18
	  	 10.13	 Further Assurances	 18
	  	 10.14	 Severability	 18

 
	 	
ii	 

LICENSING AND
DISTRIBUTION AGREEMENT  

        This
LICENSING AND DISTRIBUTION AGREEMENT (this “Agreement”), dated December
13, 2005, by and between BRADLEY PHARMACEUTICALS, INC., a Delaware corporation with an
address at 383 Route 46 West, Fairfield, New Jersey (“Bradley”), and PAR
PHARMACEUTICAL, INC., a Delaware corporation with an address at One Ram Ridge Road, Spring
Valley, New York (“Par”). 

        WHEREAS,
Par has developed certain intellectual property, including its rights under the ANDAs (as
defined below), necessary or useful to make, use and sell the pharmaceutical product
identified on Exhibit A hereto (the “Product”); 

        WHEREAS,
  Par and Bioglan Pharma, Inc. (now known as BPI Corp.), a Delaware corporation
  (“Bioglan”), have entered into that certain Distribution Agreement,
  dated as of December 27, 2000 (the “Original Agreement”),
  relating to the supply and distribution of doxycycline monohydrate tablets and
  capsules; 

        WHEREAS,
Par, Bioglan and Quintiles Ireland Limited, a company incorporated in the Republic of
Ireland (“Quintiles”), have entered into that certain Assignment of
Distribution Agreement (the “Assignment”), pursuant to which, among other
matters, (i) Bioglan assigned all of its right, title and interest in and to the
Original Agreement to Quintiles, (ii) Quintiles assumed certain obligations of
Bioglan under the Original Agreement, (iii) Par consented to the foregoing assignment
and assumption and (iv) the parties amended certain provisions of the Original
Agreement, all as set forth therein; 

        WHEREAS,
Par and Quintiles have entered into that certain Second Amendment to Distribution
Agreement and First Amendment to Assignment of Distribution Agreement, dated as of
September 11, 2003, pursuant to which Par and Quintiles amended the Assignment and
further amended the Original Agreement, as amended, all as set forth therein; 

        WHEREAS,
Par and Quintiles have entered into that certain Third Amendment to Distribution
Agreement, dated as of April 13, 2004, pursuant to which Par and Quintiles further
amended the Original Agreement, as amended, all as set forth therein; and 

        WHEREAS,
  pursuant to that certain Consent and Agreement, dated as of July 9, 2004,
  Quintiles assigned all of its right, title and interest in and to the Original
  Agreement, as amended, to Bradley (the Original Agreement, as amended by the
  Assignment, the Second Amendment, the Third Amendment and the Consent and Agreement,
  and as may hereafter be amended from time to time, is hereinafter referred to
  as the “Amended Agreement”); 

        WHEREAS,
pursuant to the Amended Agreement, Bradley is having made, selling and distributing the
Product under the brand name Adoxa® (the “Branded Product”); and 

        WHEREAS,
Par desires to license from Bradley certain rights licensed to Bradley under the Amended
Agreement, and Bradley desires to grant Par such rights, to enable Par and its Affiliates
and designee(s) to manufacture and distribute in the Territory a generic (non-branded) 

 
	 	
1	 

version of the Product in all strengths and dosage forms under the ANDA except 50 mg
and 100 mg capsules (the “Generic Product”), all upon the terms and
conditions set forth herein. 

        NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants and
obligations contained herein, Par and Bradley hereby agree as follows: 

       1.
  DEFINITIONS

        “Act”
means the Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the
rules and regulations promulgated thereunder. 

        “Affiliate”
means, with respect to any Person, any other Person controlled by, controlling or under
common control with such Person, where control means more than 50% ownership or voting
rights and/or the power to direct management or policy. 

        “Amended
  Agreement” has the meaning set forth in the recitals hereto. 

        “ANDA”
means either, and “ANDAs” means both, of the abbreviated new drug
applications numbers 065055 and 065070 filed by Par and maintained by the ANDA Holder with
the FDA for the manufacture and sale of the Product in the Territory, as the same may be
supplemented and/or amended from time to time. 

        “ANDA
Holder” means Par, unless and until such time as the applicable ANDA is purchased
by Bradley, at which time the ANDA Holder with respect to such ANDA for purposes hereof
shall mean Bradley. 

        “Branded
Product” has the meaning set forth in the recitals hereto. 

        “cGMP”
means the current Good Manufacturing Practices regulations of the FDA (as in effect from
time to time) contained in 21 C.F.R. pts. 210 and 211. 

        “Commercial
Launch” has the meaning set forth in Section 3.2(b) hereof. 

        “Confidential
Information” means any information that in any way shall relate to a party hereto
or an Affiliate thereof, including its products, business, know-how, methods, trade
secrets, business and marketing strategies, customer lists and technology, that shall be
furnished or disclosed to the other party, on a confidential basis, in connection with
this Agreement, and any other information that would be reasonably recognized as
confidential or proprietary information; provided, however, that
Confidential Information shall not include any information: 

        (i)
  that, at the time of its disclosure, is generally available to the general industry;
  

        (ii)
  that, after its disclosure in connection herewith, becomes generally available
  to the general industry, except as a result of a breach of this Agreement by
  the recipient of such information; 

 
	 	
2	 

        (iii)
  that becomes available to the recipient of such information from a third party
  that is not legally or contractually prohibited from disclosing such Confidential
  Information; or 

        (iv)
  that the recipient of which can demonstrate was developed by or for such recipient
  independently of, and without the use of, the Confidential Information disclosed
  to the recipient by the disclosing party or its Affiliates in connection herewith.
  

        “Cost
of Goods” means Par’s fully-allocated cost of goods of manufacturing,
packaging and labeling the Generic Product, including a proportionate share of overhead
but excluding marketing expenses, all calculated in accordance with GAAP. The Cost of
Goods shall include the price paid by Par to any third-party subcontractor (if any) for
manufacturing, packaging and/or labeling of the Generic Product. 

        “Effective
Date” means the date of this Agreement as written above. 

        “FDA”
means the United States Food and Drug Administration or any successor government agency. 

        “First
Commercial Sale” means the first sale of the Generic Product under this Agreement
by Par or its Affiliate in an arms’ length transaction to an unaffiliated third
party, which shall constitute commencement of the Commercial Launch. 

        “Force
Majeure Event” has the meaning set forth in Section 9.1 hereof. 

        “GAAP”
means U.S. generally accepted accounting principles. 

        “Generic
Product” has the meaning set forth in the recitals hereto. 

        “Gross
Margin” means Net Profit divided by Net Sales, expressed as a percentage (i.e.,
multiplied by 100). 

        “Ineligible
Person” has the meaning set forth in Section 6.3(a) hereof. 

        “Initial
Term” has the meaning set forth in Section 7.1 hereof. 

        “Intellectual
Property” has the meaning set forth in the recitals hereto. 

        “Launch
Quantities” has the meaning set forth in Section 4.2 hereof. 

        “Losses”
has the meaning set forth in Section 6.4 hereof. 

        “Net
Profit” means Net Sales less Cost of Goods. 

        “Net Profit
Split” has the meaning set forth in Section 4.3 hereof. 

        “Net
Sales” means the gross revenues invoiced by Par and derived from sales of the
Generic Product in the Territory by Par and its Affiliates, less (a) all customary
discounts, including cash and volume discounts, chargebacks, allowances, shelf stock
adjustments, rebates  

 
	 	
3	 

(including Medicaid, Medicare and similar rebates), returns, credits,
sales rejections and price protection adjustments, and (b) all customary freight,
shipping, insurance costs, duties and taxes; all of the foregoing calculated in accordance
with GAAP. 

        “Obsolete
Inventory” means inventory of the Generic Product having expiry dating of twelve
(12) months or less. 

        “Product”
has the meaning set forth in the recitals hereto. 

        “Person”
means a natural person, corporation, partnership, company or other entity. 

        “Renewal
Term” has the meaning set forth in Section 7.1 hereof. 

        “Specifications”
means the terms, requirements and conditions applicable to the Product and described in
the applicable ANDA, as the same may be supplemented and/or amended from time to time, and
as required by United States Pharmacopeia. 

        “Term”
has the meaning set forth in Section 7.1 hereof. 

        “Territory”
means the United States of America, together with its territories, possessions and
protectorates. 

        “Trademarks
and Copyrights” shall have the meaning set forth in Section 3.3(c) hereof. 

        2.
LICENSE GRANT 

        2.1
License Grant. Bradley hereby grants to Par and its Affiliates an exclusive,
royalty-bearing license of its rights under the Amended Agreement to make, have made, use,
import, offer for sale, sell and distribute the Generic Product in the Territory during
the Term. 

        3.
GENERIC PRODUCT DEVELOPMENT, MANUFACTURING AND DISTRIBUTION 

        3.1
Change of Tablet and Capsule Imprint. Par shall, subject to FDA approval, change
the tablet and capsule imprint of the Generic Product to differentiate the Generic Product
from the Branded Product. The tablet and capsule imprint of the Generic Product shall be
determined by Par, subject to Bradley’s consent, which shall not be unreasonably
withheld, conditioned or delayed. 

        3.2
Appointment; Commercial Launch; Supply and Distribution. (a) Bradley hereby
appoints Par as its sole and exclusive distributor for the Generic Product in the
Territory, and Par hereby accepts such appointment and agrees to act as such sole and
exclusive distributor, all upon the terms and conditions set forth herein. During the
Term, Bradley shall not market, promote, encourage, exploit, offer to sell, sell or
otherwise dispose of any generic (non-branded) doxycycline monohydrate tablet or capsule
product that is A/B rated to the Product, except in any dosage form and strength not
covered by this Agreement, (i) within the Territory or (ii) outside the 

 
	 	
4	 

Territory where it knows such product will be distributed within the Territory. During the
Term, Par shall not market, promote, encourage, exploit, offer to sell, sell or otherwise
dispose of any generic (non-branded) doxycycline monohydrate tablet or capsule product
that is A/B rated to the Product, except in any dosage form and strength not covered by
this Agreement, (i) within the Territory or (ii) outside the Territory where it
knows such product will be distributed within the Territory. 

        (b)
  Par shall have the discretion to launch such combinations of Generic Product
  strengths and dosage forms as it chooses, subject to Bradley’s prior approval.
  Par and Bradley shall confer and mutually agree upon the timing of the commercial
  launch of the Generic Product (the “Commercial Launch”), taking
  into account the actions required to be undertaken by Par and Bradley pursuant
  to Section 3.1 hereof and current and anticipated market conditions. Manufacturing,
  sales and marketing of the Generic Product in the Territory will be the sole
  responsibility of Par, which shall have the sole right and discretion to make
  all marketing and pricing strategies and decisions. 

        (c)
  Par shall, directly or through its Affiliates and designees, manufacture and
  maintain in inventory Generic Product to meet its forecasted requirements for
  the Commercial Launch in the Territory. Par may, in its discretion and at its
  expense, subcontract to a third party the manufacturing, packaging and/or labeling
  of the Generic Product, and at Par’s request, the ANDA Holder shall, at
  its own expense, file a supplement to the ANDA, based upon the information provided
  by Par, to obtain all FDA and other regulatory approval necessary for the manufacturing,
  packaging and/or labeling of the Generic Product by such subcontractor. 

        (d)
  Following the First Commercial Sale, Par shall use commercially reasonable efforts
  to market and promote sales of the Generic Product in the Territory in a manner
  generally consistent with Par’s marketing and sales of its other similarly-situated
  generic products in the Territory; provided, that Par shall not advertise
  the Generic Product in any trade journal without Bradley’s prior consent.
  

        3.3
Packaging. (a) Par shall package and label the Generic Product for sale in the
Territory with packaging and labels conforming with FDA requirements under the applicable
ANDA and shall determine the contents of the labels and artwork on all finished labeled
units, subject to the prior approval of Bradley, which approval shall not be unreasonably
withheld, conditioned or delayed; provided, that Bradley may, in its sole
discretion, withhold its approval for Par to market or sell the Generic Product in blister
or unit-dose packaging. Par shall be responsible for the cost of the initial inventory of
labels for the Generic Product. 

        (b)
  Thereafter, each of Par and Bradley may make changes to the labels, product
  inserts and other labeling for the Generic Product, subject to the requirements
  of applicable laws and regulations and the prior approval of the other party
  hereto, which shall not be unreasonably withheld, conditioned or delayed; provided,
  that Bradley may, in its sole discretion, withhold its approval to sell the
  Generic Product in blister or unit-dose packaging. Any such changes shall be
  promptly submitted by the applicable ANDA Holder (with the cooperation of the
  other party hereto) to all applicable governmental agencies and other third
  parties responsible for the reviewing and/or approval of the labels, product
  inserts and other labeling, if required. Par will not implement packaging or
  labeling changes until the applicable ANDA Holder obtains any 

 
	 	
5	 

required FDA
approval or makes the required FDA notification, as applicable. The           parties
shall share equally the actual cost incurred by Par of any such labels,
          packaging and product inserts rendered obsolete due to a change precipitated by
          the FDA or other regulatory requirements. Subject to the foregoing, Par shall
be           responsible for the actual cost incurred by Par of any labels, product
inserts           and other labeling rendered obsolete due to a change directly
precipitated by           Par, and Bradley shall be responsible for the actual cost
incurred by Par of any           labels, product inserts and other labeling rendered
obsolete due to a change           directly precipitated by Bradley.  

        (c)
  Subject to the foregoing, Par shall be responsible for selecting, maintaining,
  and enforcing trademarks, logos, slogans, designs, copyrights, emblems, insignias,
  trade dress and other protectable intellectual property rights (“Trademarks
  and Copyrights”) to be used in connection with the manufacture and
  sale of the Generic Product. Par shall own the entire right, title and interest
  in and to such Trademarks and Copyrights. Notwithstanding the foregoing, Par
  shall not knowingly adopt or use any Trademarks and Copyrights owned by Bradley
  and used by Bradley in connection with the manufacture and sale of the Branded
  Product. Bradley shall not use the Trademarks and Copyrights of Par without
  the prior written authorization of Par. 

        4.
  FINANCIAL TERMS. 

        4.1
Cost of Tablet and Capsule Imprint Change. The costs and expenses incurred by Par
or its Affiliates in the performance of its obligations set forth in Section 3.1 hereof
shall be borne solely by Par, except that Par and Bradley shall each bear one-half of the
cost of tooling associated with the manufacture of the Generic Product. Bradley shall
promptly pay Par upon Par’s submission of any invoice detailing such costs and
expenses. 

        4.2
Cost of Obsolete Inventory. Schedule 4.2 hereto sets forth the parties’
forecasted requirements of the Generic Product for the Commercial Launch (the
“Launch Quantities”). Par shall use commercially reasonable efforts,
after completing its obligations under Section 3.1 hereof, to manufacture and maintain in
inventory the Launch Quantities in preparation for the Commercial Launch. Par and Bradley
from time to time may amend the volume of Launch Quantities set forth on
Schedule 4.2 by mutual written agreement. Bradley shall be responsible for
Par’s Cost of Goods associated with any portion of the Launch Quantities that
constitutes Obsolete Inventory. Bradley shall promptly pay Par upon remittance of an
invoice detailing such costs. Such invoicing shall be in accordance with Par’s policy
and practice in expensing obsolete inventory. Except as set forth herein, Bradley shall
not be responsible for reimbursing Par for the cost of Obsolete Inventory. 

        4.3
Net Profit Split. Par shall pay to Bradley an amount equal to 50% of the Net
Profit, and Par shall retain an amount equal to 50% of the Net Profit (such allocation of
Net Profit being referred to herein the “Net Profit Split”). Par shall
pay Bradley’s share of the Net Profit Split to Bradley quarterly, within forty-five
(45) days after the close each calendar quarter, accompanied by a reasonably-detailed
calculation of such Net Profit Split. Par shall keep true and accurate books of account
and shall keep and maintain all records and documents necessary for Bradley to ascertain
its share of the Net Profit Split due under this Agreement. 

        4.4
Late Payments. In the event of a late payment under this Article 4, the payor shall
pay to the payee interest calculated on a daily basis on the overdue payment from the 

 
	 	
6	 

date
such payment was due to the date such payment is received by the payee at a rate of 1.0%
per calendar month. 

        4.5
Change in Circumstances. If, at any time during the Term following the First
Commercial Sale, either party’s share of the Net Profit Split is less than
(a) five (5%) percent of Net Sales over the course of any two (2) consecutive
calendar years (not including any partial calendar year) or (b) $500,000 in any full
calendar year; then, upon written notice by either party to the other, the parties shall
in good faith attempt to negotiate (i) early termination of the Agreement or
(ii) a sublicense to a third party of the distribution and marketing of the Generic
Product in the Territory. 

        5.
CERTAIN UNDERTAKINGS 

        5.1
Generic Product Complaints and Adverse Drug Experiences. Par shall be responsible
for handling all Generic Product complaints and for notifying Bradley within thirty (30)
days of receipt of any such complaint where such notification is required by FDA
regulation. Par shall notify Bradley of any report of serious and unexpected adverse drug
experience concerning the Generic Product within five (5) business days of its receipt of
the report, or earlier if required by applicable law and regulations and so requested by
Bradley, and provide Bradley with information as required by applicable law and
regulations and so requested by Bradley in order for Bradley to comply with the
post-marketing reporting requirements in accordance with 21 C.F.R. § 314.80
and 21 C.F.R. § 314.81. 

        5.2
Generic Product Recall. (a) In the event of any recall or seizure of any Generic
Product, Bradley shall be responsible for one-half, and Par shall be responsible for
one-half, of the aggregate transportation costs, taxes, freight insurance, handling and
reasonable and verifiable out-of-pocket costs incurred in respect of such recalled or
seized Generic Product (collectively, the “Recall Expenses”);
provided, that, (i) in the event and to the extent that any recall or seizure
of any Generic Product arises out of any improper act or omission by Par, its Affiliates
or any third party subcontractor engaged by Par, Par shall be responsible (as between
Bradley and Par) for the Recall Expenses associated with such recall or seized Generic
Product, and (ii) if, and after such time as, Bradley becomes the ANDA Holder of the
applicable ANDA, in the event and to the extent that any recall or seizure of any Generic
Product arises out of any improper act or omission by Bradley, its Affiliates or any third
party subcontractor engaged by Bradley, Bradley shall be responsible (as between Par and
Bradley) for the Recall Expenses associated with such recall or seized Generic Product. 

        (b)
  For purposes of this Section 5.2, “recall” means (i) any
  action by Par, Bradley or any Affiliate of either to recover title to or possession
  of any Generic Product sold or shipped (including, but not limited to, market
  withdrawal) and/or (ii) any decision by Par not to sell or ship Generic
  Product to third parties that would have been subject to recall if it had been
  sold or shipped, in each case taken in the good faith belief that such action
  was appropriate under the circumstances. For purposes of this Section 5.2,
  "seizure” means any action by any governmental agency to detain or
  destroy any Generic Product. 

        (c)
  Par shall control all recall activities, and Bradley shall cooperate with Par
  and provide such assistance as Par reasonably requests with respect thereto.
  Par and Bradley shall 

 
	 	
7	 

keep the other fully informed
  in writing of any notification or other information, whether received directly
  or indirectly, that could reasonably be expected to (i) affect the safety
  or effectiveness of the Generic Product, (ii) result in liability issues
  or otherwise necessitate recall action on the part of either party or (iii)
  result in recall or seizure of any Generic Product. Par shall be responsible,
  in its good-faith discretion, for determining whether or not such circumstances
  necessitate a recall of the Generic Product and shall carry out any recall activities
  that it deems appropriate with respect thereto; provided, that, if Par
  determines not to undertake a recall and Bradley reasonably believes that a
  recall is required under applicable law, then Bradley may undertake and carry
  out such recall. Par and Bradley shall reasonably cooperate with each other
  in carrying out any such recall or seizure. The applicable ANDA Holder will
  be responsible for assuring that any such recall is closed-out with the FDA,
  unless the FDA shall otherwise require. 

        5.3
Facility Maintenance; Inspection; Reports. (a) Par shall (or shall obtain the
agreement of its third-party manufacturer and/or packager, if applicable, to) use
commercially reasonable efforts to maintain and operate the manufacturing and packaging
facility designated in the ANDAs and implement such quality control procedures required so
as to meet the requirements of FDA regulations and so as to be able to perform timely its
obligations hereunder. Par shall (and shall obtain the agreement of any third-party
manufacturer and/or packager, if applicable, to) permit quality assurance representatives
of Bradley reasonably acceptable to Par to inspect such facilities not more than once per
calendar year upon reasonable notice, during normal business hours and on a confidential
basis. Bradley shall cause its quality assurance representatives to provide Par with a
written report of the results of any such inspection simultaneously with the provision of
such report to Bradley. If such inspecting party finds any non-compliance during any such
inspection with respect to the Generic Product, Par shall (and shall obtain the agreement
of any third-party manufacturer and/or packager, if applicable, to) diligently rectify
such non-compliance and implement appropriate procedures with a view to avoiding
repetition of such non-compliance; provided, that, if Par disagrees with the
conclusions of such inspecting party, it shall so notify Bradley in writing, and the
parties shall cooperate in good faith to resolve such dispute and, in the event that the
parties shall be unable to resolve such dispute within thirty (30) calendar days from the
date of Par’s notice pursuant to this Section 5.3 or such other time period mutually
agreeable to the parties, the parties shall submit such dispute to a mutually
satisfactory, non-Affiliated third-party consultant. The determination of such consultant
shall be final and binding on the parties, and the costs therefor shall be borne by the
parties in proportion to the percentage of fault attributed to each party by such
consultant. 

        (b)
  If Par or any third-party manufacturer and/or packager of the Generic Product
  receives an FDA Form 483 (“Notice of Observations”) evidencing
  any non-compliance with respect to the Generic Product, Par shall (and shall
  obtain the agreement of any third-party manufacturer and/or packager, if applicable,
  to) diligently rectify such non-compliance and implement appropriate procedures
  with a view to avoiding repetition of such non-compliance. Par shall provide
  Bradley with a copy of any FDA Form 483 (which may be redacted with respect
  to information unrelated to the Generic Product and as otherwise necessary to
  preserve the confidentiality of sensitive information) received at the conclusion
  of an FDA inspection relating to the Generic Product. 

        (c)
  If, for supply reasons or compliance reasons, Par subcontract to a third party
  the manufacturing, packaging and/or labeling of the Generic Product, such subcontracting
  shall be 

 
	 	
8	 

in Par’s discretion and at Par’s expense, and
          the applicable ANDA Holder shall, at its own expense, file a supplement to the
          ANDA, based upon the information provided by Par, to obtain all FDA and other
          regulatory approval necessary for the manufacturing, packaging and/or labeling
          of the Generic Product by such subcontractor.  

        5.4
Filing Requirements and Maintenance. The ANDA Holder shall promptly comply with all
FDA requirements with respect to the Generic Product, including all filing and reporting
requirements necessary to keep such ANDA current with the FDA and all payment obligations
with respect to required fees and costs associated with such ANDA and any other regulatory
approvals; provided, that Par shall be responsible for (a) drug listings,
formulary submissions and Par’s NDC number and (b) such compliance with other
FDA, DEA and all other regulations applicable only to a distributor of the Generic Product
as can be achieved by Par, given regulatory requirements. As reasonably requested by
Bradley, if Bradley is the ANDA Holder, Par shall supply to Bradley samples of finished
labeled units of the Generic Product and otherwise reasonably assist Bradley with such
filing and reporting requirements. Par shall be responsible for all stability studies that
may be required for ongoing marketing and sale of the Generic Product and shall conduct
such stability studies in compliance with the ANDAs. 

        5.5
Insurance. Each of Bradley and Par shall (and shall cause their respective
Affiliates, as required, to), promptly after the Effective Date and extending through the
remaining term of this Agreement and for a period of not less than 36 months following the
termination or expiration of this Agreement, carry or be subject to coverage under (as a
named insured), product liability insurance in an amount of not less than Ten
Million Dollars ($10,000,000) combined single limit, which insurance will be written
on a "claims-made” policy basis with an insurance carrier rated at least
‘A’ by Bests Rating Service or a comparable rating by a comparable rating
service. Each party shall provide the other party with evidence of coverage contemplated
hereby, in the form of certificates of insurance, as reasonably requested. 

        5.6
Audit Right. Par shall maintain true and complete books of account containing an
accurate record of all data necessary for proper assessment of the Net Profit Split
(including Cost of Goods, Net Sales and Net Profit). Bradley shall have the right, through
an independent certified public accountant, to examine Par’s books of account related
to such matters during regular business hours, on reasonable prior notice (but not more
than once in any calendar year), within three (3) years after the end of the calendar year
in which Bradley’s share of the Net Profit Split was paid by Par for the purpose of
verifying the accuracy of such matters. The parties agree that information furnished to
Bradley as a result of any such examination shall be limited to a written statement by
such certified public accountant to the effect that it has reviewed the books of account
of Par and either (i) Par’s calculations are correct or (ii) setting forth
any required adjustments thereto; and Bradley shall ensure that any such written statement
is provided concurrently to Par. If any such audit shows any underpayment or overpayment
by Par, a correcting payment shall be made within thirty (30) days after receipt of the
written statement described above. The costs and expenses of such audit shall be borne by
Bradley; provided, however, if such audit shows an underpayment by Par
exceeding $10,000 in any calendar year, Par shall reimburse Bradley for its reasonable
third-party costs of such audit. 

        5.7
Publicity. Neither party shall issue or release any media release or public
announcement (including, without limitation, any announcements made via any posting on the 

 
	 	
9	 

World Wide Web or Internet) or other similar publicity in any country announcing the
existence of this Agreement or any term or condition of this Agreement or the
relationships created by this Agreement without prior written consent of the other party
and the prior agreement of the other party on the relevant wording relating to the
Agreement or term or condition of the Agreement. The parties shall not issue or release
any joint statement utilizing Bradley’s or its Affiliate’s or Par’s or its
Affiliate’s corporate identifiers, including, without limitation, any public
announcement or advertisement, without the prior written approval of Bradley or Par, as
applicable. Notwithstanding the foregoing, each party shall have the right to issue media
releases, immediately and without prior consent of the other party, that disclose any
information required by the rules and regulations of the Securities and Exchange
Commission, any securities exchange on which a party’s or its Affiliate’s
capital stock may be traded, or any federal, state or foreign law or regulation;
provided, that the disclosing party shall use commercially reasonable efforts to
(a) notify the other party prior to such disclosure, (b) provide the other party
with a copy of the relevant wording relating to the Agreement or term or condition of the
Agreement, and (c) seek confidential treatment of any information that the other
party reasonably requests to be maintained as confidential. 

        6.
WARRANTIES; INDEMNIFICATION; AND LIMITATION OF LIABILITY. 

        6.1
Certain Representations, Warranties and Covenants of Par. (a) Par hereby
represents and warrants to Bradley that (i) Par has the requisite power and authority
to enter into this Agreement and to perform its obligations hereunder; (ii) the
execution, delivery and performance of this Agreement have been duly authorized by all
necessary action on the part of Par; and (iii) the terms of this Agreement do not
conflict with or breach any agreement to which Par or any Affiliate is a party or by which
Par or any Affiliate is otherwise bound or violate any applicable law. 

        (b)
  Par hereby warrants and covenants to Bradley that (i) any trademarks of
  Par that are to be utilized in connection with the labeling and packaging of
  the Generic Product are (or will be) the property of Par and may be lawfully
  used as directed by Par; and (ii) all Generic Product distributed by it
  hereunder shall be manufactured, tested, packaged, labeled, stored and handled
  in accordance with the Specifications most recently provided by Bradley to Par
  and cGMP in effect at the time of manufacturing and testing and that, at the
  time of distribution, such Generic Product: (A) will meet the Specifications
  or, if Bradley is the ANDA Holder, will meet the Specifications most recently
  provided by Bradley to Par, and will not be adulterated or misbranded within
  the meaning of the Act, as in effect at the time of delivery; and (B) will
  not be an article which may not be introduced into interstate commerce under
  the provisions of Sections 404 and 505 of the Act. 

        (c)
  Par hereby further represents, warrants and covenants to Bradley that, for so
  long as Par is the ANDA Holder, (i) any filings to be made by Par or its
  Affiliates with the FDA in connection with the Product shall be accurate, complete
  and truthful when filed and made in good faith upon the best information available
  to Par and its Affiliates at such time; and (ii) the ANDA and all other
  such regulatory filings with the FDA in connection with the Product will be
  amended, supplemented or otherwise updated in a timely manner whenever the information
  contained in any of them is no longer accurate, complete and truthful. 

 
	 	
10	 

THE FOREGOING WARRANTIES IN THIS
SECTION 6.1 ARE MADE BY PAR EXPRESSLY IN LIEU OF ANY OTHER EXPRESS OR IMPLIED WARRANTIES,
INCLUDING, BUT NOT BY WAY OF LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE. 

        6.2
Certain Representations, Warranties and Covenants of Bradley. (a) Bradley
hereby represents and warrants to Par that (i) Bradley has the requisite corporate
power and authority to enter into this Agreement and to perform it obligations hereunder;
(ii) the execution, delivery and performance of this Agreement have been duly
authorized by all necessary action on the part of Bradley; and (iii) the terms of
this Agreement do not conflict with or breach any agreement to which Bradley or any
Affiliate is a party or by which Bradley or any Affiliate is otherwise bound or violate
any applicable law. 

        (b)
  Bradley hereby further represents, warrants and covenants to Par that, during
  such time (if any) that Bradley is the ANDA Holder, (i) any filings to
  be made by Bradley or its Affiliates with the FDA in connection with the Product
  shall be accurate, complete and truthful when filed and made in good faith upon
  the best information available to Bradley and its Affiliates at such time; and
  (ii) the ANDA and all other such regulatory filings with the FDA in connection
  with the Product will be amended, supplemented or otherwise updated in a timely
  manner whenever the information contained in any of them is no longer accurate,
  complete and truthful. 

THE FOREGOING WARRANTIES IN THIS
SECTION 6.2 ARE MADE BY BRADLEY EXPRESSLY IN LIEU OF ANY OTHER EXPRESS OR IMPLIED
WARRANTIES, INCLUDING, BUT NOT BY WAY OF LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE. 

        6.3
Representation and Warranties with Regard to Status.  

        (a)
  Bradley hereby represents and warrants to Par that neither it nor any of its
  Affiliates is prohibited by any law, rule or regulation or by any order, directive
  or policy from selling the Generic Product or other pharmaceutical products
  within the Territory and that neither Bradley nor any of its Affiliates is a
  Person that is listed by a United States federal agency as debarred, suspended,
  or otherwise ineligible for federal programs in the United States, its territories
  and protectorates (an “Ineligible Person”) or listed by a United
  States federal agency as proposed for debarment or suspension. 

        (b)
  Par hereby represents and warrants to Bradley that neither it nor any of its
  Affiliates that is or will be a manufacturer of the Generic Product is prohibited
  by any law, rule or regulation or by any order, directive or policy from selling
  the Generic Product or other pharmaceutical products and that neither Par nor
  any such Affiliate is an Ineligible Person or listed by a United States federal
  agency as proposed for debarment or suspension. 

        6.4
Par’s Indemnification Obligations. Par shall indemnify and hold Bradley and
its Affiliates and their respective officers, directors, stockholders, employees and
agents harmless from and against, and pay or reimburse, any claim, action, suit,
proceeding, loss, liability, damage or expense (including reasonable attorneys’ fees)
(“Losses”) arising, directly or indirectly, 

 
	 	
11	 

as a result of Par’s or
its Affiliates’ negligent acts or omissions, willful wrongful acts, or breach of any
of its representations, warranties, covenants or other obligations hereunder;
provided, however, that Par shall not be required to indemnify Bradley with
respect to any Losses to the extent arising from or related to Bradley’s or its
Affiliates’ negligent acts or omissions, willful wrongful acts or Bradley’s
breach of its representations, warranties, covenants or other obligations hereunder, or
from information supplied by Bradley or its Affiliates to Par or contained in regulatory
filings or correspondence prepared or delivered by Bradley or its Affiliates. 

        6.5
Bradley’s Indemnification Obligations. Bradley shall indemnify and hold Par
and its Affiliates and their respective officers, directors, stockholders, employees and
agents harmless from and against, and pay or reimburse, any Losses arising, directly or
indirectly, as a result of Bradley’s or its Affiliates’ negligent acts or
omissions, willful wrongful acts or breach of any of its representations, warranties,
covenants or other obligations hereunder; provided, however, that Bradley
shall not be required to indemnify Par with respect to any Losses to the extent arising
from or related to Par’s or its Affiliates’ negligent acts or omissions, willful
wrongful acts or Par’s breach of its representations, warranties, covenants or other
obligations hereunder, or from information supplied by Par or its Affiliates to Bradley or
contained in regulatory filings or correspondence prepared or delivered by Par or its
Affiliates. 

        6.6
  Indemnification Procedures. With respect to indemnification for a third-party
  action, claim or liability under this Article 6, a party that intends to claim
  indemnification hereunder (the “indemnitee”) shall notify the
  other party (the “indemnitor”) promptly in writing of such
  third-party action, claim or liability in respect of which the indemnitee believes
  it is entitled to claim indemnification; provided, that the failure to
  give timely notice to the indemnitor shall not release the indemnitor from any
  liability to the indemnitee except to the extent the indemnitor is materially
  prejudiced thereby. The indemnitor shall have the right, by written notice to
  the indemnitee, to assume the defense of any such action or claim, within the
  fifteen (15)-day period after the indemnitor’s receipt of written notice
  of any action or claim, with counsel of the indemnitor’s choice and at
  the sole cost of the indemnitor. If the indemnitor so assumes such defense,
  the indemnitee may participate therein through counsel of its choice, but at
  the sole cost of the indemnitee. If the indemnitor fails to assume such defense
  and/or to diligently prosecute the same, the indemnitee may assume such defense
  at the indemnitor’s sole expense. The party not assuming the defense of
  any such claim shall render all reasonable assistance to the party assuming
  such defense, and all reasonable out-of-pocket costs of such assistance shall
  be for the account of the indemnitor. No such claim shall be settled other than
  by the party defending the same, and then only with the prior written consent
  of the other party, which consent shall not be unreasonably withheld or delayed;
  provided, however, that the indemnitee shall have (a) no
  obligation to consent to any settlement of any such action or claim that (i) imposes
  on the indemnitee any monetary or other liability or obligation that cannot
  be assumed and performed in full by the indemnitor or (ii) adversely affects
  the indemnitee’s rights hereunder or damages its reputation or business,
  and (b) no right to withhold its consent to any settlement of any such
  action or claim if the settlement involves only the payment of money by the
  indemnitor or its insurer and the indemnitor or its insurer agrees in writing
  to make such payment. EXCEPT WITH RESPECT TO INDEMNIFICATION FOR THIRD-PARTY
  CLAIMS OR DAMAGES RESULTING FROM PAR’S COMMERCIAL LAUNCH OF THE GENERIC
  PRODUCT WITHOUT BRADLEY’S CONSENT, IN NO EVENT WILL EITHER PARTY BE LIABLE
  FOR ANY SPECIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING ANY LOSS OF INCOME,
  LOSS OF 

 
	 	
12	 

PROFITS, COSTS OF
SUBSTITUTION, COSTS OF COVER OR INCREASED CAPITAL COSTS, REGARDLESS OF THE FORM OR NATURE
OF ACTION, WHETHER IN CONTRACT, BREACH OF WARRANTY, STRICT LIABILITY, EQUITY, INDEMNITY,
NEGLIGENCE, INTENTIONAL CONDUCT, TORT OR OTHERWISE, EVEN IF SUCH DAMAGES WERE FORESEEABLE
OR IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

        7.
TERM AND TERMINATION. 

        7.1
Term. This Agreement shall commence on the Effective Date and continue, unless
otherwise earlier terminated in accordance herewith, for a period that shall extend ten
(10) years from the date of the First Commercial Sale of the Generic Product (the
“Initial Term”). Thereafter, this Agreement shall be automatically
renewed for successive one-year periods (each, a “Renewal Term”
and collectively with the Initial Term, the “Term”), unless a party
shall otherwise notify the other in writing at least ninety (90) days prior to the
expiration of the Initial Term or any Renewal Term. 

        7.2
Termination for Breach. (a) If either party commits a breach or default in the
performance or observance of any of its material obligations under this Agreement, and
such breach or default continues for a period of sixty (60) days after delivery by the
other party of written notice reasonably detailing such nonperformance, then the
non-breaching or non-defaulting party shall have the right to terminate this Agreement,
with immediate effect, by giving written notice to the breaching or defaulting party. If
the nonperforming party disputes the asserted nonperformance in writing within thirty (30)
days after notice of nonperformance, the matter shall be referred to the dispute
resolution procedures set forth in Section 10.1 hereof. 

        (b)
  Either party may terminate this Agreement upon thirty (30) days’ prior
  written notice if the other party is legally prohibited from performing its
  obligations hereunder or becomes (or its Affiliate becomes) an Ineligible Person
  in respect of the Generic Product. 

        7.3
Termination for Bankruptcy. This Agreement shall automatically terminate upon
(i) either party’s initiation of any proceeding in bankruptcy, reorganization or
arrangement for the appointment of a receiver or trustee to take possession of its assets
or similar proceeding under the law for release of creditors, (ii) either
party’s making a general assignment for the benefit of its creditors, or (iii) a
third party’s initiation of any proceeding in bankruptcy, reorganization or
arrangement for the appointment of a receiver or trustee to take possession of the assets
of a party hereto or similar proceeding under the law for release of creditors by or
against a party hereto, and such proceeding continues unstayed for more than sixty (60)
days. 

        7.4
Termination for Change in Circumstances. This Agreement may be terminated by either
party upon written notice to the other if, despite good faith negotiations pursuant to
Section 4.5 hereof, the parties are unable to reach agreement pursuant to Section 4.5
hereof within thirty (30) days after the provision of notice thereunder. 

        7.5
Post-Termination. (a)  If this Agreement is terminated by Bradley pursuant to
Section 7.4 or by Par pursuant to Section 7.2 or 7.3 hereof, Par shall have the
right to sell its existing inventory of Generic Product and Bradley shall reimburse Par
for the cost of its raw  

 
	 	
13	 

materials ordered prior to such termination for the manufacture of
the Generic Product. If this Agreement expires at the end of the Term pursuant to Section
7.1 hereof, Par shall have the right to sell its existing inventory of Generic Product. 

        (b)
  The termination or expiration of this Agreement shall not affect any payment
  or other obligations or liabilities that have accrued prior to the date of such
  termination or expiration, and the parties shall retain all rights and remedies
  (at law or in equity) in respect of any breach thereof. In the event that Par
  disposes of existing inventory of Generic Product pursuant to Section 7.5(a)
  after termination of this Agreement pursuant to Section 7.2, 7.3 or 7.4,
  such termination shall not relieve Par of its obligation under Section 4.3
  to pay Bradley’s share of the Net Profit Split with respect to sales in
  the Territory of the Generic Product hereunder after the date of termination.
  

        8.
CONFIDENTIALITY. 

        8.1
Treatment of Confidential Information. Except as required by applicable laws and
regulations (including rules or regulations of any exchange upon which a party’s
capital stock may be traded) or as otherwise provided in this Article 8, during the Term,
and for three (3) years thereafter, each party shall hold in confidence, and may not use
for purposes other than those contemplated by this Agreement or disclose to a third party
(except as specifically set forth herein or with the express prior written consent of the
other party) any and all Confidential Information. 

        8.2
Limits on Disclosure. (a) Without limiting the generality of the foregoing, each
party may disclose Confidential Information to those employees or agents who need to
receive the Confidential Information in order to further the activities contemplated by
this Agreement. Each party shall take reasonable precautions to safeguard the Confidential
Information, including obtaining appropriate commitments and enforceable confidentiality
agreements. Each party understands and agrees that the wrongful disclosure of Confidential
Information may result in serious and irreparable damage to the other party, that the
remedy at law for any breach of this covenant may be inadequate, and that the party
seeking redress hereunder shall be entitled to injunctive relief, without prejudice to any
other rights and remedies to which such party may be entitled. 

        (b)
  It is acknowledged that Confidential Information may be obtained by a party
  from the other party not only in writing or other tangible form (including electronic),
  but also through discussions between each party’s respective representatives,
  demonstrations, observations and other intangible methods. Any verbal disclosure
  of Confidential Information by a party shall be reduced to writing and provided
  to the other party within forty-five (45) days. 

        (c)
  Notwithstanding the foregoing, each party shall have the right with the exercise
  of reasonable discretion, and insofar as practical under written confidentiality
  agreements having provisions no less stringent than those contained herein,
  to make disclosures of such portions of Confidential Information to third party
  consultants, attorneys, contractors, advisors, Affiliates and governmental agencies
  where, in the recipient’s judgment, such disclosure is beneficial to the
  development, approval or marketing of the Generic Product pursuant to this Agreement.
  

 
	 	
14	 

        (d)
  Except as otherwise set forth in this Agreement, upon the termination or expiration
  of this Agreement and at the written request of the disclosing party, the receiving
  party shall return all Confidential Information of the disclosing party (including
  all copies, excerpts and summaries thereof contained on any media) or destroy
  such Confidential Information at the option of the disclosing party; provided,
  that the receiving party may retain one copy of all Confidential Information
  of the disclosing party for its legal records. 

        9.
  FORCE MAJEURE. 

        9.1
Effects of Force Majeure. No party hereto shall be held liable or responsible for
failure or delay in fulfilling or performing any of its obligations under this Agreement
(other than the payment of money) if such failure or delay is caused by, without
limitation, acts of God, acts of the public enemy, fire, explosion, flood, drought, war,
terrorists, riot, sabotage, embargo, strikes or other labor disputes, intervention of
governmental agency (subject to Section 7.2(b)), or by any other event or circumstance of
like or different character to the foregoing beyond the reasonable control and without the
fault or negligence of the affected party (a “Force Majeure Event”). Such
excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such
Force Majeure Event, such party shall promptly resume performance hereunder. 

        9.2
Notice of Force Majeure. Each party agrees to give the other party prompt written
notice of the occurrence of any Force Majeure Event, the nature thereof and the extent to
which the affected party will be unable to perform its obligations hereunder. Each party
further agrees to use reasonable efforts to correct or otherwise address the Force Majeure
Event as soon as practicable and to give the other parties prompt written notice when it
is again fully able to perform such obligations. 

        10.
MISCELLANEOUS. 

        10.1
Dispute Resolution. The parties recognize that a bona fide dispute as
to certain matters may, from time to time, arise during the Term that relates to a
party’s rights and/or obligations hereunder. In the event of the occurrence of such a
dispute, either party may, by written notice to the other party, have such dispute
referred to their respective officers, designated below, or their successors, for
attempted resolution by good faith negotiation within thirty (30) days after such notice
is received. Such designated officers are as follows: 

	        For
      Par:	  	Scott Tarriff,
      President and Chief Executive Officer

	        For Bradley:
      	  	Daniel Glassman,
      President and Chief Executive Officer 

  

In the event that the designated
officers are not able to resolve the dispute within such thirty (30)-day period, or such
other period of time as the parties may mutually agree to in writing, each party shall
have the right to pursue any and all remedies available at law or in equity. 

        10.2
Independent Contractors. The relationship between Par, on the one hand, and
Bradley, on the other hand, is that of independent contractors and nothing herein shall
be deemed to constitute or create the relationship of partners, joint venturers nor of
principal and agent between Par on the one hand and Bradley on the other hand. Neither
party shall have any  

 
	 	
15	 

express or implied right or
authority to assume or create any obligations on behalf of or in the name of the other
party or to bind the other party to any contract, agreement or undertaking with any third
party.  

        10.3
Assignment. This Agreement may be assigned and delegated by either party
(a) to an Affiliate of such party or (b) in connection with any sale, merger or
other business combination involving all or substantially all of such party’s assets
or capital stock. Except as set forth in the preceding sentence, neither this Agreement
nor any other rights or obligations hereunder shall be assigned or delegated by either
party without the prior written consent of the other party. 

        10.4
Governing Law; Waiver of Jury Trial. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of New Jersey. Each party hereby
consents to the exclusive jurisdiction of Federal and New York State courts located in
Manhattan, New York, and hereby waives any objection to venue or forum laid therein. Each
party hereby agrees that service of process by certified mail, return receipt requested,
shall constitute personal service for all purposes hereof. EACH PARTY HEREBY WAIVES ITS
RIGHT TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR
RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, IN ANY ACTION,
PROCEEDING OR OTHER LITIGATION OF ANY TYPE BROUGHT BY ANY PARTY AGAINST THE OTHER, WHETHER
WITH RESPECT TO CONTRACT CLAIMS, TORT CLAIMS OR OTHERWISE. THIS WAIVER SHALL APPLY TO ANY
SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT. 

        10.5
No Implied Waiver. No failure or delay on the part of either party hereto to
exercise any right, power or privilege hereunder or under any instrument executed pursuant
hereto shall, in itself, operate as a waiver; nor shall any single or partial exercise of
any right, power or privilege preclude any other or further exercise thereof or the
exercise of any other right, power or privilege. 

        10.6
Notice. All notices required to be given hereunder shall be in writing and shall be
given by personal delivery, via facsimile transmission followed by U.S. mail, by a
nationally recognized overnight carrier or by registered or certified mail, postage
prepaid with return receipt requested. Notices shall be addressed to the parties as
follows: 

	 If to Bradley:	 Bradley Pharmaceuticals, Inc.
	  	 383 Route 46 West
	  	 Fairfield, NJ 07004-2402
	  	 Attn:	 Daniel Glassman, President and
        Chief Executive Officer
	  	 Facsimile No.: (973) 575-5366
	  	  	  
	 If to Par:	 Par Pharmaceutical, Inc.
	  	 300 Tice Boulevard
	  	 Woodcliff Lake, NJ 07677
	  	 Attn:	 Scott Tarriff, President and Chief Executive
        Officer
	  	  	 Thomas Haughey, General Counsel

 
	 	
16	 

	 	 	Michael Graves, Vice
      President, Strategic Planning and
	 	 	Corporate Development
	 	Facsimile
      No.: (201) 802-4622
	  	  	  
	 With a copy	 Kirkpatrick & Lockhart
      Nicholson Graham LLP
	 (which shall	 599 Lexington Ave.
	 not constitute	 New York, NY 10022
	 notice) to:	 Attn:	 Stephen R. Connoni, Esq.
	  	  	 Barry J. Gilman, Esq.
	  	 Facsimile No.: (212)
      536-3901

Notices delivered personally shall be
deemed communicated as of actual receipt; notices sent via facsimile transmission shall be
deemed communicated as of receipt by the sender of written confirmation of transmission
thereof; notices sent via overnight courier shall be deemed received as of one business
day following sending; and notices mailed shall be deemed communicated as of three (3)
business days after proper mailing. A party may change its address by written notice sent
in accordance with this Section 10.6. 

        10.7
Amendments. Any amendment or modification of this Agreement shall be valid
only if made in writing and signed by the parties hereto. 

        10.8
Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed an original and both of which shall constitute a single document. A
facsimile signature of an authorized signatory of either party shall be valid and binding
and constitute due execution and delivery of this Agreement by such party. 

        10.9
Interpretation. The Section headings contained in this Agreement are for the
convenience of reference only and shall not affect the meaning or interpretation of this
Agreement. As used in this Agreement, any reference to the masculine, feminine or neuter
gender shall include all genders, the plural shall include the singular, and the singular
shall include the plural. Unless the context otherwise requires, the term
“party” when used herein means a party hereto. References herein to a party or
other Person include their respective successors and assigns. The words
“includes” and “including” when used herein shall be deemed to
followed by the phrase “without limitation” unless such phrase otherwise
appears. Unless the context otherwise requires, references herein to Articles, Sections,
Exhibits and Schedules shall be deemed references to Articles and Sections of, and
Exhibits and Schedules to, this Agreement. Unless the context otherwise requires, the
words “hereof,” “hereby” and “herein” and words of similar
meaning when used in this Agreement refer to this Agreement in its entirety and not to any
particular Section or provision hereof. With regard to each and every term and condition
of this Agreement, the parties understand and agree that the same has or have been
mutually negotiated, prepared and drafted, and that, if, at any time, the parties desire
or are required to interpret or construe any such term or condition or any agreement or
instrument subject thereto, no consideration shall be given to the issue of which party
actually prepared, drafted or requested any term or condition of this Agreement. 

        10.10
Entire Agreement. This Agreement constitutes the entire understanding between the
parties with respect to the subject matter hereof and supersedes all prior contracts, 

 
	 	
17	 

agreements and understandings
related to the same subject matter between the parties. The parties intend this Agreement
to be a complete statement of the terms of their understanding.  

        10.11
Benefit; Binding Effect. This Agreement shall be binding upon and shall inure to
the benefit of the parties hereto and their respective successors and permitted assigns. 

        10.12
Survival. Notwithstanding anything to the contrary contained in this Agreement, the
provisions of Sections 5.1 (to the extent of post-termination complaints and reporting
obligations), 5.2 (to the extent of post-termination recall activities), 5.4 (to the
extent of post-termination distribution of Generic Product), 5.5, 5.6, 7.5 and Articles 1,
6, 8 and 10 shall survive, in accordance with their respective terms, any termination of
this Agreement. 

        10.13
Further Assurances. The parties agree that they shall take all appropriate actions,
including the execution or filing of any documents or instruments, that may be reasonably
necessary or advisable to carry out the intent and accomplish the purposes of any of the
provisions hereof. 

        10.14
Severability. In the event that any provision of this Agreement shall be held
invalid or unenforceable for any reason by a court of competent jurisdiction, such
provision or part thereof shall be considered separate from the remaining provisions of
this Agreement, which shall remain in full force and effect. Such invalid or unenforceable
provision shall be deemed revised to effect, to the fullest extent permitted by applicable
law, the intent of the parties as set forth herein. 

[SIGNATURE PAGE
FOLLOWS]  

 
	 	
18	 

        IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date
first above written by their duly authorized representatives. 

	 	 BRADLEY PHARMACEUTICALS,
      INC.
	 	  	  	  
	 	By: 	       /s/
        Daniel Glassman
        

	 	  	 Name:	 Daniel Glassman
	 	  	 Title:	 President and Chief Executive Officer
	 	  	  	  
	 	PAR PHARMACEUTICAL,
      INC.
	 	  	  	  
	 	By: 	       /s/
        Michael Graves
        

	 	  	 Name:	 Michael Graves
	 	  	 Title:	 Vice President, Strategic Planning and Corporate
        Development

 
	 	
19	 

Schedule
  4.2 

Launch Quantity 

	

	Description

      (Strength) 	 	Bottle

      Size (Tabs

      per Bottle) 	 	Number of

      Batches 	 	Batch Size

      (Tabs) 	 	Tablets

      per Bottle

      Size 	 	Number of

      Bottles 
	

	50 mg	 	[*]’s	 	[*]	 	[*]	 	[*]	 	[*]
	

	 	 	 	 	 	 	 	 	 	 	 
	

	75 mg	 	[*]’s	 	[*]	 	[*]	 	[*]	 	[*]
	75 mg	 	[*]’s	 	 	 	[*]	 	[*]
	

	 	 	 	 	 	 	 	 	 	 	 
	

	100 mg	 	[*]’s	 	[*]	 	[*]	 	[*]	 	[*]
	100 mg	 	[*]’s	 	 	 	[*]	 	[*]
	

	[*] 	 Certain information on this page has been omitted
      and filed separately with the Securities and Exchange Commission. Confidential
      treatment has been requested with respect to the omitted portions. 

          

 
	 	
1	 

EXHIBIT A  

Product 

The pharmaceutical product
doxycycline monohydrate tablets and capsules in all strengths under the ANDAs. 

 
	 	
1exv10w1

 

Exhibit 10.1

5,000,000 Shares

SEMITOOL, INC.

Common Stock

PLACEMENT AGENCY AGREEMENT

December 15, 2005

Needham & Company, LLC

445 Park Avenue

New York, New York 10022

Ladies and Gentlemen:

     Semitool, Inc., a Montana corporation (the “Company”), proposes to issue and sell to certain
investors (collectively, the “Investors”) up to an aggregate of 3,000,000 shares of the Company’s
common stock, no par value per share (the “Common Stock”), and Raymon F. Thompson (the “Selling
Stockholder”) proposes to sell to the Investors up to an aggregate of 2,000,000 shares of Common
Stock (the 5,000,000 shares to be sold collectively by the Company and the Selling Stockholder to
the Investors, the “Shares”). The Company and the Selling Stockholder desire to engage Needham &
Company, LLC as their exclusive placement agent (the “Placement Agent”) in connection with the
issuance and sale of the Shares. The Shares are described more fully in the Prospectuses that are
referred to below.

     The Company and the Selling Stockholder confirm their agreements with the Placement Agent as
follows:

     1. Agreement to Act as Placement Agent.

     (a) On the basis of the representations, warranties and agreements of the Company and the
Selling Stockholder herein contained and subject to all of the terms and conditions of this
Agreement, the Company and the Selling Stockholder engage the Placement Agent to act as their
exclusive placement agent in connection with the issuance and sale of the Shares and the Placement
Agent hereby agrees, as an agent of the Company and the Selling Stockholder, to use its
commercially reasonable efforts to solicit offers to purchase the Shares upon the terms and
conditions set forth in the Prospectuses (as defined below). Prior to the earlier of (i) the date
on which this Agreement is terminated and (ii) the Closing Date (as defined below), the Company and
the Selling Stockholder shall not, without the prior consent of the Placement Agent, solicit or
accept offers to purchase Common Stock (except that the Company may do so pursuant to the exercise
of options or warrants to purchase shares of Common Stock that are outstanding as of the date
hereof) otherwise than through the Placement Agent in accordance herewith.

     (b) As compensation for the services rendered hereunder, on the Closing Date (as defined
below), the Company shall pay to the Placement Agent, by wire transfer of immediately available
U.S. funds payable to the order of the Placement Agent, to an account or accounts designated by the
Placement Agent, an amount equal to 5.4% of the gross proceeds received by the Company from its
sale of the Shares, and the Selling Stockholder shall pay to the Placement Agent, by wire transfer
of immediately available U.S. funds payable to the order of the Placement Agent, to an account or
accounts designated by the Placement Agent, an amount equal to 5.4% of the gross proceeds received
by the Selling Stockholder from its sale of the Shares (the aggregate of the fees paid by the
Company and the Selling Stockholder, the “Fee”). The Placement Agent may, in its discretion, retain
other brokers or dealers to act as sub-agents on the Placement Agent’s behalf in connection with
the offering of the Shares.

 

 

     (c) This Agreement shall not give rise to a commitment by the Placement Agent or any of its
affiliates to underwrite or purchase any of the Shares or otherwise provide any financing, and the
Placement Agent shall have no authority to bind the Company and the Selling Stockholder in respect
of the sale of any Shares. Each of the Company and the Selling Stockholder shall have the sole
right to accept offers to purchase the Shares and may reject any such offer in whole or in part.
The Placement Agent shall have the right, in its discretion reasonably exercised, without notice to
the Company or the Selling Stockholder, to reject any offer to purchase Shares received by it, in
whole or in part, and any such rejection shall not be deemed a breach of its agreement contained
herein. The sale of the Shares shall be made pursuant to purchase agreements in the form attached
hereto as Exhibit A (the “Purchase Agreements”).

     2. Delivery
and Payment. (a) Concurrently with the execution and delivery of this Agreement,
the Company, the Selling Stockholder, the Placement Agent and Wells Fargo Bank, N.A., as escrow
agent (the “Escrow Agent”), shall enter into an escrow agreement (the “Escrow Agreement”), pursuant
to which an escrow account (the “Escrow Account”) will be established for the benefit of the
Company, the Selling Stockholder and the Investors. Prior to the Closing, each such Investor shall
deposit into the Escrow Account an amount equal to the product of (x) the number of Shares such
Investor has agreed to purchase and (y) the purchase price per share determined by the Purchase
Agreements (the “Purchase Amount”). The aggregate of such Purchase Amounts is herein referred to
as the “Escrow Funds.” On the Closing Date, the Escrow Agent will disburse the Escrow Funds to the
Company, the Selling Stockholder and the Placement Agent as provided in the Escrow Agreement and
the Company shall cause its transfer agent to deliver the Shares purchased by such Investors.

     (b) Subject to the terms and conditions hereof, delivery of the Shares shall be made by the
Company and the Selling Stockholder to the Investors, and payment of the purchase price shall be
made by the Investors, at the office of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA,
at 10:00 a.m., New York City time, on or before December 21, 2005 or at such time on such other
date as may be agreed upon in writing by the Company, the Selling Stockholder and the Placement
Agent but in no event prior to the date on which the Escrow Agent shall have received all of the
Escrow Funds (such date of delivery and payment is hereinafter referred to as the “Closing Date”).
The Shares shall be delivered, through the facilities of The Depository Trust Company, to such
persons, and shall be registered in such name or names and shall be in such denominations, as the
Placement Agent may request by written notice to the Company and the Selling Stockholder at least
one business day before the Closing Date. The cost of original issue tax stamps and other transfer
taxes, if any, in connection with the issuance and/or delivery of the Shares by the Company and the
Selling Stockholder to the respective Investors shall be borne by the Company.

     3. Representations and Warranties of the Company. The Company represents, warrants and
covenants to the Placement Agent that:

     (a) The Company meets the requirements for the use of Form S-3, a registration statement
(Registration No. 333-39492) on Form S-3 relating to the Shares being offered by the Company,
including a base prospectus relating to the Shares being offered by the Company (the “Base
Prospectus”) and such amendments thereof as may have been required to the date of this Agreement,
has been prepared by the Company under the provisions of the Securities Act of 1933, as amended
(the “Act”), and the rules and regulations (collectively referred to as the “Rules and
Regulations”) of the Securities and Exchange Commission (the “Commission”) thereunder, and has been
filed with and has been declared effective by the Commission, and the offering of the Shares by the
Company complies with Rule 415 under the Act. A final prospectus supplement to the Base Prospectus
relating to the Shares being offered by the Company and the offering thereof will be filed promptly
by the Company with the Commission in accordance with Rule 424(b) of the Rules and Regulations.
Such registration statement at any given time, including the amendments thereto to such time, the
exhibits and any schedules thereto at such time, the documents otherwise deemed to be a part
thereof or included therein by the Rules and Regulations, and any registration statement relating
to the offering of Shares by the Company contemplated by this Agreement and filed pursuant to Rule
462(b) of the Rules and Regulations, is herein called the “Company Registration Statement.” The
term “Prospectus Supplement” means the final prospectus supplement to the Base Prospectus relating
to the Shares being offered by the Company and the offering thereof as first filed with the
Commission pursuant to Rule 424(b) of the Rules and Regulations. The term “Company Prospectus” means the Base Prospectus together with the Prospectus
Supplement, except that if such Base Prospectus is amended or supplemented on or prior to the date
on which the Prospectus Supplement was first filed pursuant to Rule 424(b) of the Rules and
Regulations, the term “Company Prospectus” shall mean the

2

 

Base Prospectus as so amended or
supplemented and as supplemented by the Prospectus Supplement. A registration statement
(Registration No. 333-112964) on Form S-3 relating to the Shares being offered by the Selling
Stockholder, and such amendments thereof as may have been required to the date of this Agreement,
has been prepared by the Company and the Selling Stockholder under the provisions of the Act and
the Rules and Regulations of the Commission thereunder, and has been filed with and has been
declared effective by the Commission, and the offering of the Shares by the Selling Stockholder
complies with Rule 415 under the Act. Such registration statement at any given time, including the
amendments thereto to such time, the exhibits and any schedules thereto at such time, the documents
otherwise deemed to be a part thereof or included therein by the Rules and Regulations, and any
registration statement relating to the offering of Shares by the Selling Stockholder contemplated
by this Agreement and filed pursuant to Rule 462(b) of the Rules and Regulations, is herein called
the “Selling Stockholder Registration Statement,” and together with the Company Registration
Statement, the “Registration Statements.” The term “Selling Stockholder Prospectus” means the
prospectus included in the Selling Stockholder Registration Statement together with the prospectus
filed pursuant to Rule 424(b) of the Rules and Regulations, as it may be amended or supplemented,
and together with the Company Prospectus, the “Prospectuses.” Any reference herein to the Company
Registration Statement, the Selling Stockholder Registration Statement, the Registration
Statements, the Base Prospectus, the Prospectus Supplement, the Company Prospectus, the Selling
Stockholder Prospectus or the Prospectuses shall be deemed to refer to and include the documents
incorporated by reference therein, and any reference herein to the terms “amend,” “amendment” or
“supplement” with respect to the Company Registration Statement, the Selling Stockholder
Registration Statement, the Registration Statements, the Base Prospectus, the Prospectus
Supplement, the Company Prospectus, the Selling Stockholder Prospectus or the Prospectuses shall be
deemed to refer to and include the filing of any document under the Securities Exchange Act of
1934, as amended (the “Exchange Act”), after the time the Registration Statement initially became
effective (the “Effective Date”), the date of any preliminary prospectus or the date of the
Prospectuses, as the case may be, and deemed to be incorporated therein by reference. The term
“Issuer Free Writing Prospectus” means an “issuer free writing prospectus” as defined in Rule 433
of the Rules and Regulations.

     (b) No order preventing or suspending the use of the Base Prospectus, the Prospectus
Supplement, the Prospectuses or any Issuer Free Writing Prospectus has been issued by the
Commission, and no stop order suspending the effectiveness of the Registration Statements
(including any related registration statement filed pursuant to Rule 462(b) under the Act) or any
post-effective amendment thereto has been issued, and no proceeding for that purpose has been
initiated or threatened by the Commission. On the Effective Date, on the date (if any) the Base
Prospectus, the Prospectus Supplement, or the Prospectuses are first filed with the Commission
pursuant to Rule 424(b), at all times during the period through and including the Closing Date and
when any post-effective amendment to the Registration Statements becomes effective or any amendment
or supplement to the Prospectuses is filed with the Commission, the Registration Statements and the
Prospectuses (as amended or as supplemented if the Company shall have filed with the Commission any
amendment or supplement thereto), including the financial statements included or incorporated by
reference in the Prospectuses, did and will comply in all material respects with all applicable
provisions of the Act, the Exchange Act, the rules and regulations under the Exchange Act (the
“Exchange Act Rules and Regulations”), and the Rules and Regulations did and will contain all
statements required to be stated therein in accordance with the Act, the Exchange Act, the Exchange
Act Rules and Regulations, and the Rules and Regulations. On the Effective Date and when any
post-effective amendment to the Registration Statements becomes effective, no part of the
Registration Statements, the Base Prospectus or any such amendment or supplement thereto did or
will contain an untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements therein not misleading. At the
Effective Date, the date the Base Prospectus or any amendment or supplement to the Base Prospectus,
including the Prospectus Supplement, is filed with the Commission, the date of first use of the
Prospectus Supplement, and the Closing Date, the Prospectuses did not and will not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading.
The foregoing representations and warranties in this Section 3(b) do not apply to any statements or
omissions made in reliance on and in conformity with information relating to the Placement Agent
furnished in writing to the Company by the Placement Agent specifically for inclusion in the
Registration Statements, the Base Prospectus, the Prospectus Supplement or Prospectuses or any
amendment or supplement thereto. The Company acknowledges that the statements set forth in the
last paragraph under the heading “Plan of Distribution” in the Prospectus Supplement constitute the only information relating to the
Placement Agent furnished in writing to the Company by the Placement Agent specifically for
inclusion in the Registration

3

 

Statements, the Base Prospectus, the Prospectus Supplement, or the
Prospectuses or any amendment or supplement thereto.

     (c) The documents that are incorporated by reference in the Base Prospectus, the Prospectus
Supplement and the Prospectuses or from which information is so incorporated by reference, when
they became or become effective or were or are filed with the Commission, as the case may be,
complied or will comply in all material respects with the requirements of the Act or the Exchange
Act, as applicable, and the Rules and Regulations or the Exchange Act Rules and Regulations, as
applicable; and any documents so filed and incorporated by reference subsequent to the Effective
Date shall, when they are filed with the Commission, comply in all material respects with the
requirements of the Act or the Exchange Act, as applicable, and the Rules and Regulations or the
Exchange Act Rules and Regulations, as applicable.

     (d) No Issuer Free Writing Prospectus includes any information that conflicts with the
information contained in the Registration Statements, including any document incorporated by
reference therein that has not been superseded or modified. If at any time following issuance of
an Issuer Free Writing Prospectus any event occurred or occurs as result of which such Issuer Free
Writing Prospectus would conflict with the information in the Registration Statements, the
Prospectuses or the Prospectus Supplement or include an untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements therein, in the light of the
circumstances then prevailing, not misleading, the Company will notify promptly the Placement Agent
and, if requested by the Placement Agent, will prepare and furnish without charge to the Placement
Agent an Issuer Free Writing Prospectus or other document that will correct such conflict,
statement or omission. The foregoing two sentences do not apply to statements in or omissions from
an Issuer Free Writing Prospectus made in reliance on and in conformity with information relating
to the Placement Agent furnished in writing to the Company by the Placement Agent specifically for
inclusion therein, it being understood and agreed that the only such information furnished by or on
behalf of the Placement Agent consists of the information described as such in Section 3(b) above.

     (e) The Company does not own, and at the Closing Date will not own, directly or indirectly,
any shares of stock or any other equity or long-term debt securities of any corporation or have any
equity interest in any corporation, firm, partnership, joint venture, association or other entity,
other than the subsidiaries listed in Exhibit 21.1 to the Company’s Annual Report on Form 10-K for
the fiscal year ended September 30, 2005 (the “Subsidiaries”). The Company and each of its
Subsidiaries is, and at the Closing Date will be, a corporation duly organized, validly existing
and in good standing under the laws of its jurisdiction of incorporation. The Company and each of
its Subsidiaries has, and at the Closing Date will have, full power and authority to conduct all
the activities conducted by it, to own or lease all the assets owned or leased by it and to conduct
its business as described in the Registration Statements and the Prospectuses. The Company and
each of its Subsidiaries is, and at the Closing Date will be, duly licensed or qualified to do
business and in good standing as a foreign corporation in all jurisdictions in which the nature of
the activities conducted by it or the character of the assets owned or leased by it makes such
license or qualification necessary, except to the extent that the failure to be so qualified or be
in good standing would not materially and adversely affect the Company and its Subsidiaries, taken
as a whole, or their respective businesses, properties, business prospects, conditions (financial
or other) or results of operations, taken as a whole (such effect is referred to herein as a
“Material Adverse Effect”). All of the outstanding shares of capital stock of each Subsidiary have
been duly authorized and validly issued and are fully paid and nonassessable, and are owned by the
Company free and clear of all claims, liens, charges and encumbrances; there are no securities
outstanding that are convertible into or exercisable or exchangeable for capital stock of any
Subsidiary. The Company and its Subsidiaries are not, and at the Closing Date will not be, engaged
in any discussions or a party to any agreement or understanding, written or oral, regarding the
acquisition of an interest in any corporation, firm, partnership, joint venture, association or
other entity where such discussions, agreements or understandings would require amendment to the
Registration Statements pursuant to applicable securities laws. Complete and correct copies of the
articles of incorporation, by-laws or other organizational documents of the Company and each of its
Subsidiaries and all amendments thereto have been delivered to the Placement Agent, and no changes
therein will be made subsequent to the date hereof and prior to the Closing Date.

     (f) The Company has authorized, issued and outstanding capital stock as set forth under the
caption “Capitalization” in the Prospectus Supplement as of the date set forth therein. All of the
outstanding shares of capital stock of the Company have been duly authorized and validly issued,
are fully paid and nonassessable and

4

 

were issued in compliance with all applicable state and
federal securities laws; the Shares have been duly authorized and when issued and paid for as
contemplated herein will be validly issued, fully paid and nonassessable; and no preemptive or
similar rights exist with respect to any of the Shares or the issue and sale thereof. The
description of the capital stock of the Company included or incorporated by reference in the
Registration Statements and the Prospectuses is, and at the Closing Date will be, complete and
accurate in all material respects. Except as set forth in the Prospectuses, the Company does not
have outstanding, and at the Closing Date will not have outstanding, any options to purchase, or
any rights or warrants to subscribe for, or any securities or obligations convertible into, or any
contracts or commitments to issue or sell, any shares of capital stock, or any such warrants,
convertible securities or obligations. No further approval or authority of shareholders or the
Board of Directors of the Company will be required for the issuance and sale of the Shares as
contemplated herein. The certificates evidencing the Shares are in due and proper legal form and
have been duly authorized for issuance by the Company.

     (g) The financial statements and schedule included or incorporated by reference in the
Registration Statements or the Prospectuses present fairly in all material respects the financial
condition of the Company and its consolidated Subsidiaries as of the respective dates thereof and
the results of operations and cash flows of the Company and its consolidated Subsidiaries for the
respective periods covered thereby, all in conformity with generally accepted accounting principles
applied on a consistent basis throughout the entire period involved, except as otherwise disclosed
in the Prospectus. No other financial statements or schedules of the Company are required by the
Act, the Exchange Act, the Exchange Act Rules and Regulations or the Rules and Regulations to be
included in the Registration Statements or the Prospectuses. PricewaterhouseCoopers LLP (the
“Accountants”), who have reported on such financial statements and schedule, are independent
accountants with respect to the Company as required by the Act and the Rules and Regulations and
Rule 3600T of the Public Company Accounting Oversight Board (“PCAOB”). The summary and selected
consolidated financial and statistical data included or incorporated by reference in the
Registration Statements present fairly the information shown therein and have been compiled on a
basis consistent with the audited financial statements presented in the Registration Statements.

     (h) Subsequent to the respective dates as of which information is given in the Registration
Statements and the Prospectuses and prior to or on the Closing Date, except as set forth in or
contemplated by the Registration Statements and the Prospectuses, (i) there has not been and will
not have been any change in the capitalization of the Company (other than in connection with the
exercise of options to purchase the Company’s Common Stock granted pursuant to the Company’s stock
option plans from the shares reserved therefor as described in the Registration Statements), or any
Material Adverse Effect arising for any reason whatsoever, (ii) neither the Company nor any of its
Subsidiaries has incurred nor will any of them incur, except in the ordinary course of business as
described in the Prospectus, any material liabilities or obligations, direct or contingent, nor has
the Company or any of its Subsidiaries entered into nor will it enter into, except in the ordinary
course of business as described in the Prospectuses, any material transactions other than pursuant
to this Agreement and the transactions referred to herein and (iii) the Company has not and will
not have paid or declared any dividends or other distributions of any kind on any class of its
capital stock.

     (i) The Company is not, will not become as a result of the transactions contemplated hereby,
and will not conduct its business in a manner that would cause it to become, an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment
company,” as such terms are defined in the Investment Company Act of 1940, as amended.

     (j) Except as set forth in the Registration Statements and the Prospectuses, there are no
actions, suits or proceedings pending or, to the knowledge of the Company, threatened against or
affecting the Company, or any of its Subsidiaries or any of its or their respective officers in
their capacity as such, nor any basis therefor, before or by any federal or state court,
commission, regulatory body, administrative agency or other governmental body, domestic or foreign,
wherein an unfavorable ruling, decision or finding would reasonably be expected to have a Material
Adverse Effect.

     (k) The Company and each Subsidiary has, and at the Closing Date will have, performed all the
obligations required to be performed by it, and is not, and at the Closing Date will not be, in
default, under any contract or other instrument to which it is a party or by which its property is bound or
affected, which default would reasonably be expected to have a Material Adverse Effect. To the
knowledge of the Company, no other party under any contract or other instrument to which it or any
of its Subsidiaries is a party is in default in any respect

5

 

thereunder, which default might have a
Material Adverse Effect. Neither the Company nor any of its Subsidiaries is, or at the Closing
Date will be, in violation of any provision of its articles of incorporation, by-laws or other
organizational documents.

     (l) No consent, approval, authorization or order of, or any filing or declaration with, any
court or governmental agency or body is required for the consummation by the Company of the
transactions on its part contemplated herein, except such as have been obtained under the Act or
the Rules and Regulations and such as may be required under state securities or Blue Sky laws or
the by-laws and rules of the National Association of Securities Dealers, Inc. (the “NASD”) in
connection with the public offering of the Shares.

     (m) The Company has full corporate power and authority to enter into this Agreement and each
Purchase Agreement. This Agreement has been duly authorized, executed and delivered by the Company
and constitutes a valid and binding agreement of the Company, enforceable against the Company in
accordance with the terms hereof. Each Purchase Agreement has been duly authorized and, as of the
Closing Date, will have been executed and delivered by the Company and will constitute a valid and
binding agreement of the Company, enforceable against the Company in accordance with the terms
thereof. The Escrow Agreement has been duly authorized and, as of the Closing Date, will have been
executed and delivered by the Company and constitute a valid and binding agreement of the Company,
enforceable against the Company in accordance with the terms thereof. The performance of this
Agreement, the Purchase Agreements and the Escrow Agreement and the consummation of the
transactions contemplated hereby and thereby will not result in the creation or imposition of any
material lien, charge or encumbrance upon any of the assets of the Company pursuant to the terms or
provisions of, or result in a breach or violation of any of the terms or provisions of, or conflict
with or constitute a default under, or give any party a right to terminate any of its obligations
under, or result in the acceleration of any obligation under, the articles of incorporation,
by-laws or other organizational documents of the Company or any of its Subsidiaries, any indenture,
mortgage, deed of trust, voting trust agreement, loan agreement, bond, debenture, note agreement or
other evidence of indebtedness, lease, contract or other agreement or instrument to which the
Company or any of its Subsidiaries is a party or by which the Company, any of its Subsidiaries or
any of its or their properties is bound or affected, or violate or conflict with any judgment,
ruling, decree, order, statute, rule or regulation of any court or other governmental agency or
body applicable to the business or properties of the Company or any of its Subsidiaries.

     (n) The Company and its Subsidiaries have good and marketable title to all properties and
assets described in the Prospectuses as owned by them, free and clear of all liens, charges,
encumbrances or restrictions, except such as are described in the Prospectuses or are not material
to the business of the Company or its Subsidiaries. The Company and its Subsidiaries have valid,
subsisting and enforceable leases for the properties described in the Prospectuses as leased by
them. The Company and its Subsidiaries own or lease all such properties as are necessary to their
respective operations as now conducted or as proposed to be conducted, except where the failure to
so own or lease would not have a Material Adverse Effect.

     (o) There is no document, contract, permit or instrument, affiliate transaction or off-balance
sheet transaction (including, without limitation, any “variable interests” in “variable interest
entities,” as such terms are defined in Financial Accounting Standards Board Interpretation No. 46)
of a character required to be described in the Registration Statements or the Prospectuses or to be
filed as an exhibit to the Registration Statements that is not described or filed as required. All
such contracts to which the Company or any of its Subsidiaries is a party have been duly
authorized, executed and delivered by the Company or such Subsidiary, constitute valid and binding
agreements of the Company or such Subsidiary and are enforceable against and by the Company or such
Subsidiary in accordance with the terms thereof.

     (p) No relationship, direct or indirect, exists between or among the Company on the one hand,
and the directors, officers, shareholders, customers or suppliers of the Company on the other hand,
which is required to be described in the Prospectus and which is not so described.

     (q) No statement, representation, warranty or covenant made by the Company in this Agreement
or made in any certificate or document required by Section 8 of this Agreement to be delivered to
the Placement Agent was or will be, when made, inaccurate, untrue or incorrect.

6

 

     (r) The Company has not distributed, and will not distribute prior to the Closing Date, any
offering material in connection with the offering and sale of the Shares other than any preliminary
prospectuses, the Prospectuses, the Registration Statements and other materials, if any, permitted
by the Act. Neither the Company nor any of its directors, officers or controlling persons has
taken, directly or indirectly, any action designed, or that might reasonably be expected, to cause
or result, under the Act or otherwise, in, or that has constituted, stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Shares.

     (s) No holder of securities of the Company has rights to the registration of any securities of
the Company because of the filing of the Registration Statements, which rights have not been waived
by the holder thereof as of the date hereof.

     (t) The Common Stock is registered under Section 12(g) of the Exchange Act and the Company has
filed an application to list the Shares on the Nasdaq National Market (“NNM”), and has received
notification that the listing has been approved, subject to notice of issuance of the Shares.

     (u) Except as disclosed in or specifically contemplated by the Prospectuses (i) the Company
and each of its Subsidiaries owns or has adequate rights to use all trademarks, trade names, domain
names, patents, patent rights, mask works, copyrights, technology, know-how (including trade
secrets and other unpatented or unpatentable proprietary or confidential information, systems or
procedures), service marks, trade dress rights, and other intellectual property (collectively,
“Intellectual Property”) and has such other licenses, approvals and governmental authorizations, in
each case, sufficient to conduct its business as now conducted, and to the Company’s and its
Subsidiaries’ knowledge, none of the foregoing Intellectual Property rights owned or licensed by
the Company or any of its Subsidiaries is invalid or unenforceable, (ii) the Company has no
knowledge of any infringement by it or any of its Subsidiaries of Intellectual Property rights of
others, where such infringement could have a Material Adverse Effect, (iii) the Company is not
aware of any infringement, misappropriation or violation by others of, or conflict by others with
rights of the Company or any of its Subsidiaries with respect to, any Intellectual Property, (iv)
there is no claim being made against the Company or any of its Subsidiaries or, to the knowledge of
the Company and its Subsidiaries, any employee of the Company or any of its Subsidiaries, regarding
Intellectual Property or other infringement that could have a Material Adverse Effect, and (v) the
Company and its Subsidiaries have not received any notice of infringement with respect to any
patent or any notice challenging the validity, scope or enforceability of any Intellectual Property
owned by or licensed to the Company or any of its Subsidiaries, in each case the loss of which
patent or Intellectual Property (or loss of rights thereto) would have a Material Adverse Effect.

     (v) The Company and each of its Subsidiaries has filed all federal, state, local and foreign
income tax returns that have been required to be filed and has paid all taxes and assessments
received by it to the extent that such taxes or assessments have become due. Neither the Company
nor any of its Subsidiaries has any tax deficiency that has been or, to the knowledge of the
Company, might be asserted or threatened against it that could have a Material Adverse Effect.

     (w) The Company or its Subsidiaries own or possess all authorizations, approvals, orders,
licenses, registrations, other certificates and permits of and from all governmental regulatory
officials and bodies, necessary to conduct their respective businesses as contemplated in the
Prospectus, except where the failure to own or possess all such authorizations, approvals, orders,
licenses, registrations, other certificates and permits would not have a Material Adverse Effect.
There is no proceeding pending or overtly threatened (or any basis therefor known to the Company)
that may cause any such authorization, approval, order, license, registration, certificate or
permit to be revoked, withdrawn, cancelled, suspended or not renewed; and the Company and each of
its Subsidiaries is conducting its business in compliance with all laws, rules and regulations
applicable thereto (including, without limitation, all applicable federal, state and local
environmental laws and regulations) except where such noncompliance would not have a Material
Adverse Effect.

     (x) The Company and each of its Subsidiaries maintain insurance of the types and in the
amounts generally deemed adequate for its business, including, but not limited to, insurance
covering real and personal property owned or leased by the Company and its Subsidiaries against
theft, damage, destruction, acts of vandalism and all other risks customarily insured against, all
of which insurance is in full force and effect.

7

 

     (y) No labor disturbance by the employees of the Company or its Subsidiaries exists or, to
the knowledge of the Company, is imminent, which might have a Material Adverse
Effect.

     (z) The Company is in compliance in all material respects with all presently
applicable requirements and provisions of the Employee Retirement Income Security Act of 1974, as
amended, including the regulations and published interpretations thereunder (“ERISA”) and the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, including the regulations and
published interpretations thereunder; no “reportable event” (as defined in ERISA) has occurred with
respect to any “pension plan” (as defined in ERISA) for which the Company would have any liability;
the Company has not incurred and does not expect to incur liability under (i) Title IV of ERISA
with respect to termination of, or withdrawal from, any “pension plan” or (ii) Sections 412 or 4971
of the Internal Revenue Code of 1986, as amended, including the regulations and published
interpretations thereunder (the “Code”); and each “pension plan” for which the Company would have
any liability that is intended to be qualified under Section 401(a) of the Code is so qualified in
all material respects and nothing has occurred, whether by action or by failure to act, which would
cause the loss of such qualification.

     (aa) There has been no storage, disposal, generation, manufacture, refinement,
transportation, handling or treatment of toxic wastes, medical wastes, hazardous wastes or
hazardous substances by the Company or its Subsidiaries at, upon or from any of the property now or
previously owned or leased by the Company or its Subsidiaries in violation of any applicable law,
ordinance, rule, regulation, order, judgment, decree or permit or which would require remedial
action under any applicable law, ordinance, rule, regulation, order, judgment, decree or permit,
except for any violation or remedial action which would not have, individually or in the aggregate
with all such violations and remedial actions, a Material Adverse Effect; there has been no
material spill, discharge, leak, emission, injection, escape, dumping or release of any kind onto
such property or into the environment surrounding such property of any toxic wastes, medical
wastes, solid wastes, hazardous wastes or hazardous substances due to or caused by the Company or
its Subsidiaries or with respect to which the Company has knowledge, except for any such spill,
discharge, leak, emission, injection, escape, dumping or release which would not have, individually
or in the aggregate with all such spills, discharges, leaks, emissions, injections, escapes,
dumpings and releases, a Material Adverse Effect; and the terms “hazardous wastes,” “toxic wastes,”
“hazardous substances” and “medical wastes” shall have the meanings specified in any applicable
local, state, federal and foreign laws or regulations with respect to
environmental protection.

     (bb) Neither the Company nor any of its Subsidiaries nor, to Company’s knowledge, any of its
or their respective employees or agents at any time during the last five years has (i) made any
unlawful contribution to any candidate for foreign office, or failed to disclose fully any
contribution in violation of law, or (ii) made any payment to any federal or state governmental
officer or official, or other person charged with similar public or quasi-public duties, other than
payments required or permitted by the laws of the United States or any jurisdiction thereof.

     (cc) The books, records and accounts of the Company and its Subsidiaries accurately and fairly
reflect in all material respects, in reasonable detail, the transactions in, and dispositions of,
the assets of, and the results of operations of, the Company and its Subsidiaries. The Company and
each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide
reasonable assurances that (i) transactions are executed in accordance with management’s general or
specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the
Company’s consolidated financial statements in accordance with generally accepted accounting
principles and to maintain asset accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.

     (dd) The Company has established and maintains disclosure controls and procedures (as such
term is defined in Rule 13a-15(e) under the Exchange Act), which (i) are designed to ensure that
material information relating to the Company, including its Subsidiaries, is made known to the
Company’s principal executive officer and its principal financial officer by others within those
entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated for
effectiveness; and (iii) are effective in all material respects to perform the functions for which
they were established.

     (ee) Based on the evaluation of its disclosure controls and procedures, the Company is not
aware of (i) any significant deficiency or material weakness in the design or operation of internal
control over financial reporting that

8

 

is reasonably likely to adversely affect the Company’s
ability to record, process, summarize and report financial information; or (ii) any fraud, whether
or not material, that involves management or other employees who have a significant role in the
Company’s internal control over financial reporting.

     (ff) Since the date of the most recent evaluation of such disclosure controls and procedures,
there have been no significant changes in internal controls or in other factors that could
significantly affect internal controls, including any corrective actions with regard to significant
deficiencies or material weaknesses.

     (gg) The Company is in compliance in all material respects with applicable provisions of the
Sarbanes-Oxley Act of 2002 and the rules and regulations of the Commission and The Nasdaq Stock
Market that pertain thereto that are effective and is actively taking steps to ensure that it will
be in compliance in all material respects with other applicable provisions of the Sarbanes-Oxley
Act of 2002 and the rules and regulations of the Commission and The Nasdaq Stock Market that
pertain thereto upon the effectiveness of such provisions.

     (hh) There are no affiliations or associations between any member of the NASD and any of the
Company’s officers, directors, or 5% or greater securityholders, except as set forth in the
Registration Statement and the Prospectus.

     (ii) On June 16, 2000, the Company satisfied, and on December 21, 2005, the Company will
satisfy, the eligibility requirements in existence prior to October 21, 1992 for the use of a
registration statement on Form S-3 for the offering of the Shares.

     4. Representations and Warranties of the Selling Stockholder. The Selling Stockholder
represents, warrants and covenants to the Placement Agent that:

     (a) The Selling Stockholder has, and immediately prior to the Closing Date the Selling
Stockholder will have, good and valid title to the Shares to be sold by the Selling Stockholder
hereunder, free and clear of all liens, encumbrances, equities or claims; and upon delivery of such
Shares and payment therefor by the Investor, good and valid title to such shares, free and clear of
all liens, encumbrances, equities or claims, will pass to the Investor.

     (b) The Selling Stockholder has full power and authority to enter into this Agreement and each
Purchase Agreement. This Agreement has been duly executed and delivered by the Selling Stockholder
and constitutes a valid and binding agreement of the Selling Stockholder, enforceable against the
Selling Stockholder in accordance with the terms hereof. Each Purchase Agreement, as of the
Closing Date, will have been executed and delivered by the Selling Stockholder and will constitute
a valid and binding agreement of the Selling Stockholder, enforceable against the Selling
Stockholder in accordance with the terms thereof. The Escrow Agreement, as of the Closing Date,
will have been executed and delivered by the Selling Stockholder and constitute a valid and binding
agreement of the Selling Stockholder, enforceable against the Selling Stockholder in accordance
with the terms thereof.

     (c) On the Effective Date and when any post-effective amendment to the Registration Statements
becomes effective, no part of the Registration Statements, the Base Prospectus or any such
amendment or supplement thereto did or will contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements
therein not misleading. At the Effective Date, the date the Base Prospectus or any amendment or
supplement to the Base Prospectus, including the Prospectus Supplement, is filed with the
Commission, the date of first use of the Prospectus Supplement, and the Closing Date, the
Prospectuses did not and will not contain any untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The foregoing representations and warranties in this Section
4(c) do not apply to any statements or omissions made in reliance on and in conformity with
information relating to the Placement Agent furnished in writing to the Company by the Placement Agent specifically for inclusion in the Registration Statements, the Base
Prospectus, the Prospectus Supplement or Prospectuses or any amendment or supplement thereto. The
Selling Stockholder acknowledges that the statements set forth in the last paragraph under the
heading “Plan of Distribution” in the Prospectus Supplement constitute the only information
relating to the Placement Agent furnished in writing to the Company by the Placement Agent
specifically for inclusion in the Registration Statements, the Base Prospectus, the Prospectus
Supplement, or the Prospectuses or any amendment or supplement thereto.

9

 

     (d) The Selling Stockholder has no reason to believe that the representations and warranties
of the Company contained in Section 3 hereof are not true and correct, is familiar with the
Registration Statements and the Prospectuses (as amended or supplemented) and has no knowledge of
any material fact, condition or information not disclosed in the Registration Statements, as of
their respective effective dates, or the Prospectuses (or any amendment or supplement thereto), as
of the applicable filing dates, which has adversely affected or may adversely affect the business
of the Company.

     (e) The Selling Stockholder is not prompted to sell Shares by any material information
concerning the Company which is not set forth in, or incorporated by reference into, the
Prospectuses or the Registration Statements.

     5. Agreements of the Company. The Company covenants and agrees with the Placement Agent as
follows:

     (a) The Company will not, during such period as the Prospectus is required by law to be
delivered in connection with sales of the Shares or a dealer, file any amendment or supplement to
the Registration Statements or the Prospectuses, unless a copy thereof shall first have been
submitted to the Placement Agent within a reasonable period of time prior to the filing thereof and
the Placement Agent shall not have objected thereto in good faith and on reasonable grounds.

     (b) The Company will notify the Placement Agent promptly, and will confirm such advice in
writing, (i) when any post-effective amendment to the Registration Statements becomes effective,
(ii) of any request by the Commission for amendments or supplements to the Registration Statements
or the Prospectuses or for additional information, (iii) of the issuance by the Commission of any
stop order suspending the effectiveness of the Registration Statements or the initiation of any
proceedings for that purpose or the threat thereof, (iv) of the happening of any event during the
period mentioned in the second sentence of Section 4(e) that in the judgment of the Company makes
any statement made in the Registration Statements or the Prospectuses untrue or that requires the
making of any changes in the Registration Statements or the Prospectuses in order to make the
statements therein, in the light of the circumstances in which they are made, not misleading, and
(v) of receipt by the Company or any representative or attorney of the Company of any other
communication from the Commission relating to the Company, the Registration Statements, any
preliminary prospectus, the Base Prospectus, the Prospectus Supplement or the Prospectuses. If at
any time the Commission shall issue any order suspending the effectiveness of the Registration
Statements, the Company will make every reasonable effort to obtain the withdrawal of such order at
the earliest possible moment. If the Company has omitted any information from the Company
Registration Statement pursuant to Rule 430A of the Rules and Regulations or has omitted any
information from the Base Prospectus pursuant to Rule 430B or 430C of the Rules and Regulations,
the Company will comply with the provisions of and make all requisite filings with the Commission
pursuant to said Rule 430A, Rule 430B or 430C, as applicable, and notify the Placement Agent
promptly of all such filings. If the Company elects to rely upon Rule 462(b) under the Act, the
Company shall file a registration statement under Rule 462(b) with the Commission in compliance
with Rule 462(b) by 10:00 P.M., Washington, D.C. time, on the date of this Agreement, and the
Company shall at the time of filing either pay to the Commission the filing fee for such Rule
462(b) registration statement or give irrevocable instructions for the payment of such fee pursuant
to the Rules and Regulations.

     (c) The Company will furnish to the Placement Agent, without charge, one signed copy of each
of the Registration Statements and of any post-effective amendment thereto, including financial
statements and schedules, and all exhibits thereto and will furnish to the Placement Agent, without
charge, a copy of the Registration Statements and any pre- or post-effective amendment thereto,
including financial statements and schedules but without exhibits.

     (d) the Company will comply with all the provisions of any undertakings contained in the Registration Statements.

     (e) From time to time, the Company will deliver to the Placement Agent, without charge, as many copies of the
Prospectuses or any amendment or supplement thereto as the Placement Agent may reasonably request. The
Company consents to the use of the Prospectuses or any amendment or supplement thereto by the Placement Agent,
both in connection with the offering or sale of the Shares and for any period of time thereafter during which the

10

 

Prospectuses are required by law to
be delivered in connection therewith. If during such period of time any event shall occur that in
the judgment of the Company or counsel to the Placement Agent should be set forth in the
Prospectuses in order to make any statement therein, in the light of the circumstances under which
it was made, not misleading, or if it is necessary to supplement or amend the Prospectuses to
comply with law, the Company will forthwith prepare and duly file with the Commission an
appropriate supplement or amendment thereto, and will deliver to the Placement Agent, without
charge, such number of copies of such supplement or amendment to the Prospectuses as the Placement
Agent may reasonably request. The Company will not file any document under the Exchange Act or the
Exchange Act Rules and Regulations before the termination of the offering of the Shares, if such
document would be deemed to be incorporated by reference into the Prospectuses, that is not
approved by the Placement Agent after reasonable notice thereof.

     (f) Prior to any public offering of the Shares, the Company will cooperate with the Placement
Agent and counsel to the Placement Agent in connection with the registration or qualification of
the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the
Placement Agent may request; provided, that in no event shall the Company be obligated to qualify
to do business in any jurisdiction where it is not now so qualified or to take any action that
would subject it to general service of process in any jurisdiction where it is not now so subject.

     (g) The Company will, so long as required under the Rules and Regulations, furnish to its
shareholders as soon as practicable after the end of each fiscal year an annual report (including a
balance sheet and statements of income, shareholders’ equity and cash flow of the Company and its
consolidated Subsidiaries, if any, certified by independent public accountants) and, as soon as
practicable after the end of each of the first three quarters of each fiscal year, consolidated
summary financial information of the Company and its Subsidiaries, if any, for such quarter in
reasonable detail.

     (h) During the period of five years commencing on the date hereof, the Company will furnish to
the Placement Agent copies of such financial statements and other periodic and special reports as
the Company is required to distribute generally to the holders of any class of its capital stock.

     (i) The Company will make generally available to holders of its securities as soon as may be
practicable, but in no event later than the Availability Date (as defined below), an earning
statement (which need not be audited but shall be in reasonable detail) covering a period of 12
months commencing after the Effective Date that will satisfy the provisions of Section 11(a) of the
Act (including Rule 158 of the Rules and Regulations). For the purpose of the preceding sentence,
“Availability Date” means the 40th day after the end of the fourth fiscal quarter following the
fiscal quarter that includes such Effective Date, except that if such fourth fiscal quarter is the
last quarter of the Company’s fiscal year, “Availability Date” means the 75th day after the end of
such fourth fiscal quarter.

     (j) Whether or not the transactions contemplated by this Agreement are consummated or this
Agreement is terminated, the Company will pay or reimburse if paid by the Placement Agent all costs
and expenses incident to the performance of the obligations of the Company under this Agreement and
in connection with the transactions contemplated hereby, including but not limited to costs and
expenses of or relating to (i) the preparation, printing and filing of the Registration Statements
and exhibits to it, each preliminary prospectus, the Base Prospectus, each Prospectus Supplement,
the Prospectuses, and any amendment or supplement to any of the foregoing, (ii) the preparation and
delivery of certificates representing the Shares, (iii) furnishing (including costs of shipping and
mailing) such copies of the Registration Statements, the Base Prospectus, the Prospectus
Supplement, the Prospectuses and any preliminary prospectus, and all amendments and supplements
thereto, as may be requested by the Placement Agent for use in connection with the offering and
sale of the Shares, (iv) the listing of the Shares on the NNM, (v) any filings required to be made
by the Placement Agent or the Company with the NASD, and the fees, disbursements and other charges
of counsel for the Placement Agent in connection therewith or in determining the
availability of an exemption therefrom, (vi) the registration or qualification of the Shares
for offer and sale under the securities or Blue Sky laws of such jurisdictions designated pursuant
to Section 5(f), including the fees, disbursements and other charges of counsel to the Placement
Agent in connection therewith, and the preparation and printing of preliminary, supplemental and
final Blue Sky memoranda, (vii) fees, disbursements and other charges of counsel to the Company and
of the Accountants, (viii) the transfer agent for the Shares, (ix) the Escrow Agent and (x) any
travel expenses of the Company’s officers, directors and employees and any other expenses of the
Company in connection with attending or hosting meetings with prospective Investors. The Company
shall reimburse the

11

 

Placement Agent, upon request, for all out-of-pocket costs and expenses
promptly following receipt by the Company of an invoice from the Placement Agent.

     (k) The Company will not at any time, directly or indirectly, take any action designed or that
might reasonably be expected to cause or result in, or that will constitute, stabilization of the
price of the shares of Common Stock to facilitate the sale or resale of any of the Shares.

     (l) The Company will apply the net proceeds from the offering and sale of the Shares to be
sold by the Company in the manner set forth in the Company Prospectus under “Use of Proceeds.”

     (m) During the period beginning from the date hereof and continuing to and including the date
90 days after the date of the Company Prospectus, without the prior written consent of Needham &
Company, LLC, the Company will not (1) offer, sell, contract to sell, pledge, grant options,
warrants or rights to purchase, or otherwise dispose of any equity securities of the Company or any
other securities convertible into or exchangeable for its Common Stock or other equity security
(other than pursuant to employee stock option plans disclosed in the Prospectus or pursuant to the
conversion of convertible securities or the exercise of warrants in each case outstanding on the
date of this Agreement) or (2) enter into any swap or other derivatives transaction that transfers
to another, in whole or in part, any of the economic benefits or risks of ownership of shares of
Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by
delivery of Common Stock or other securities, in cash or otherwise; provided, however, that if (a)
during the last 17 days of such 90-day period the Company issues an earnings release or material
news or a material event relating to the Company occurs or (b) prior to the expiration of such
90-day period, the Company announces that it will release earnings results during the 16-day period
beginning on the last day of such 90-day period, the restrictions imposed by this Section 5(m)
shall continue to apply until the expiration of the 18-day period beginning on the issuance of the
earnings release or the occurrence of the material news or material event.

     (n) During the period of 90 days after the date of the Company Prospectus, the Company will
not, without the prior written consent of Needham & Company, LLC, grant options to purchase shares
of Common Stock at a price less than the price at which the Shares have been offered to the public.
During the period of 90 days after the date of the Company Prospectus, the Company will not file
with the Commission or cause to become effective any registration statement relating to any
securities of the Company without the prior written consent of Needham & Company, LLC.

     (o) The Company will cause each of its executive officers and directors to enter into lock-up
agreements with the Placement Agent to the effect that they will not, without the prior written
consent of Needham & Company, LLC, sell, contract to sell or otherwise dispose of any shares of
Common Stock or rights to acquire such shares according to the terms set forth in Exhibit B hereto.

     6. Further
Agreements of the Company. (a) The Company represents and agrees that, without the
prior written consent of the Placement Agent, and the Placement Agent represents and agrees that,
without the prior written consent of the Company, it has not made and will not make any offer
relating to the Shares that would constitute a “free writing prospectus” as defined in Rule 405 of
the Rules and Regulations. Any such Free Writing Prospectus the use of which has been consented to
by the Company and the Placement Agent is listed on Schedule I and herein called a “Permitted Free
Writing Prospectus.”

     (b) The Company agrees that is has treated and will treat, as the case may be, each Permitted
Free Writing Prospectus as an Issuer Free Writing Prospectus and that it has complied and will
comply, as the case may be, with
the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Permitted
Free Writing Prospectus, including timely Commission filings where required and legending.

12

 

     7. Agreements
of the Selling Stockholder. (a) The Selling Stockholder will comply with the
terms and conditions of the lock-up letter agreement that was executed between the Selling
Stockholder and the Placement Agent.

     (b) The Selling Stockholder will not at any time, directly or indirectly, take any action
designed or that might reasonably be expected to cause or result in, or that will constitute,
stabilization of the price of the shares of Common Stock to facilitate the sale or resale of any of
the Shares.

     8. Conditions of the Obligations of the Placement Agent. The obligations of the Placement
Agent hereunder are subject to the following conditions:

     (a) All filings required by Rule 424, Rule 430A, 430B and 430C of the Rules and Regulations
shall have been made. If the Company has elected to rely upon Rule 462(b), the registration
statement filed under Rule 462(b) shall have become effective by 10:00 P.M., Washington, D.C. time,
on the date of this Agreement.

     (b) (i) No stop order suspending the effectiveness of the Registration Statements shall have
been issued and no proceedings for that purpose shall be pending or threatened by the Commission,
(ii) no order suspending the effectiveness of the Registration Statements or the qualification or
registration of the Shares under the securities or Blue Sky laws of any jurisdiction shall be in
effect and no proceeding for such purpose shall be pending before or threatened or contemplated by
the Commission or the authorities of any such jurisdiction, (iii) any request for additional
information on the part of the staff of the Commission or any such authorities shall have been
complied with to the satisfaction of the staff of the Commission or such authorities, (iv) after
the date hereof no amendment or supplement to the Registration Statements or the Prospectuses shall
have been filed unless a copy thereof was first submitted to the Placement Agent and the Placement
Agent does not object thereto in good faith, and (v) the Placement Agent shall have received
certificates, dated the Closing Date and signed by the Chief Executive Officer and the Chief
Financial Officer of the Company (who may, as to proceedings threatened, rely upon the best of
their information and belief), to the effect of clauses (i), (ii) and (iii) of this paragraph.

     (c) Since September 30, 2005, (i) there shall not have been a material adverse change in the
general affairs, business, business prospects, properties, management, condition (financial or
otherwise) or results of operations of the Company or any of its Subsidiaries, whether or not
arising from transactions in the ordinary course of business, in each case other than as described
in or contemplated by the Registration Statements and the Prospectuses, and (ii) neither the
Company nor any of its Subsidiaries shall have sustained any material loss or interference with its
business or properties from fire, explosion, flood or other casualty, whether or not covered by
insurance, or from any labor dispute or any court or legislative or other governmental action,
order or decree, which is not described in the Registration Statements and the Prospectuses, if in
the judgment of the Placement Agent any such development makes it impracticable or inadvisable to
consummate the offering of the Shares.

     (d) Since the respective dates as of which information is given in the Registration Statements
and the Prospectuses, there shall have been no litigation or other proceeding instituted against
the Company, any of its Subsidiaries, or any of its or their officers or directors in their
capacities as such, before or by any federal, state or local court, commission, regulatory body,
administrative agency or other governmental body, domestic or foreign, in which litigation or
proceeding an unfavorable ruling, decision or finding would, in the judgment of the Placement
Agent, have a Material Adverse Effect or if, in the judgment of the Placement Agent, any such
development makes it impracticable or inadvisable to consummate the offering of the Shares.

     (e) Each of the representations and warranties of the Company and the Selling Stockholder
contained herein shall be true and correct in all respects (in the case of any representation or
warranty containing a materiality or Material Adverse Effect qualification) or in all material
respects at the Closing Date and all covenants and agreements contained herein to be performed on
the part of the Company or the Selling Stockholder and all
conditions contained herein to be fulfilled or complied with by the Company or the Selling
Stockholder at or prior to the Closing Date shall have been duly performed, fulfilled or complied
with.

     (f) The Placement Agent shall have received an opinion, dated the Closing Date, satisfactory
in form and substance to the Placement Agent and counsel for the Placement Agent, from Richard
Hegger, General Counsel to the Company, with respect to the following matters:

13

 

     (i) Each of the Company and Rhetech, Inc. is a corporation duly organized, validly
existing and in good standing under the laws of its jurisdiction of incorporation; has full
corporate power and authority to conduct all the activities conducted by it, to own or lease
all the assets owned or leased by it and to conduct its business as described in the
Registration Statements and Prospectuses; and is duly licensed or qualified to do business
and is in good standing as a foreign corporation in all jurisdictions in which the nature of
the activities conducted by it or the character of the assets owned or leased by it makes
such license or qualification necessary and where the failure to be licensed or qualified
would have a material and adverse effect on the business or financial condition of the
Company.

     (ii) All of the shares of capital stock of the Company issued since the Company’s
initial public offering have been duly authorized, validly issued and are fully paid and
nonassessable, and were not issued in violation of or subject to any preemptive or, to such
counsel’s knowledge, similar rights.

     (iii) The Shares have been duly authorized and, when issued and paid for as
contemplated by this Agreement and the respective Purchase Agreements, will be validly
issued, fully paid and nonassessable; and no preemptive or similar rights exist with respect
to any of the Shares or the issue and sale thereof.

     (iv) All of the outstanding shares of capital stock of Rhetech, Inc. have been duly
authorized and validly issued and are fully paid and nonassessable, and owned by the Company
free and clear of all claims, liens, charges and encumbrances; to such counsel’s knowledge,
there are no securities outstanding that are convertible into or exercisable or exchangeable
for capital stock of Rhetech, Inc.

     (v) To such counsel’s knowledge, except as disclosed in or specifically contemplated by
the Registration Statements, there are no outstanding options, warrants or other rights
calling for the issuance of, and no commitments, plans or arrangements to issue, any shares
of capital stock of the Company or any security convertible into or exchangeable or
exercisable for capital stock of the Company. The description of the capital stock of the
Company included in or incorporated by reference in the Registration Statements and the
Prospectuses conforms in all material respects to the terms thereof.

     (vi) To such counsel’s knowledge, there are no legal or governmental proceedings
pending or threatened to which the Company or any of its Subsidiaries is a party or to which
any of their respective properties is subject that are required to be described in the
Registration Statements or the Prospectuses but are not so described.

     (vii) The Company has full corporate power and authority to enter into this Agreement
and the Purchase Agreements. This Agreement and each Purchase Agreement have been duly
authorized, executed and delivered by the Company.

     (viii) The execution and delivery of this Agreement and the Purchase Agreements, the
compliance by the Company with all of the respective terms hereof and thereof and the
consummation of the transactions contemplated hereby and thereby (A) do not contravene any
provision of the Articles of Incorporation or By-Laws of the Company, (B) to such counsel’s
knowledge, will not result in the creation or imposition of any lien, charge or encumbrance
upon any of the assets of the Company or any of its Subsidiaries pursuant to the terms and
provisions of, conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, or give any party a right to terminate any of
its obligations under, or result in the acceleration of any obligation under, any material
indenture, mortgage, deed of trust, voting trust agreement, loan agreement, bond, debenture,
note agreement or other material
evidence of indebtedness, lease, contract or other agreement, document or instrument
known to such counsel to which the Company or any of its Subsidiaries is a party or by which
the Company, any of its Subsidiaries, or any of their respective properties is bound or
affected, or (C) violate or conflict with (i) any judgment, ruling, decree or order known to
such counsel or (ii) to such counsel’s knowledge, any statute, rule or regulation of any
court or other governmental agency or body, applicable to the business or properties of the
Company or any of its Subsidiaries.

14

 

     (ix) To such counsel’s knowledge, there is no document or contract of a character
required to be described in the Registration Statements or the Prospectuses or to be filed
as an exhibit to the Registration Statements that is not described or filed or incorporated
by reference as required, and each description of such contracts and documents that is
contained or incorporated by reference in the Registration Statements and Prospectuses
fairly presents in all material respects the information required under the Act and the
Rules and Regulations.

     (x) The statements under the captions “Description of Securities” and “Legal
Proceedings,” and the first sentence of “Risk Factors — Anti-takeover provisions in
our charter documents could adversely affect the rights of holders of our common stock,” in
the Prospectuses or incorporated by reference therein, insofar as the statements constitute
a summary of documents referred to therein or matters of law, are accurate summaries and
fairly and correctly present, in all material respects, such documents or matters of law
(provided, however, that such counsel may rely on representations of the Company with
respect to the factual matters contained in such statements, and provided further that such
counsel shall state that nothing has come to the attention of such counsel that leads them
to believe that such representations are not true and correct in all material respects).

     (xi) To such counsel’s knowledge, no holder of securities of the Company has rights,
which have not been waived or satisfied, to require the Company to register with the
Commission shares of Common Stock or other securities, as part of the offering contemplated
hereby.

     (xii) The Selling Stockholder has full power and authority to enter into this Agreement
and the Purchase Agreements. This Agreement and each Purchase Agreement have been duly
executed and delivered by the Selling Stockholder.

     (xiii) Upon delivery of the Shares and payment therefor by an Investor, good and valid
title to such Shares, free and clear of all liens, encumbrances, equities or claims, will
pass to such Investor.

     (g) The Placement Agent shall have received an opinion, dated the Closing Date, satisfactory
in form and substance to the Placement Agent and counsel for the Placement Agent, from Morrison &
Foerster LLP, counsel to the Company and the Selling Stockholder, with respect to the following
matters:

     (i) No consent, approval, authorization or order of, or any filing or declaration with,
any court or governmental agency or body is required for the consummation by the Company of
the transactions on its part contemplated under this Agreement or the respective Purchase
Agreements, except such as have been obtained or made under the Act or the Rules and
Regulations and such as may be required under state securities or Blue Sky laws or the
by-laws and rules of the NASD in connection with the offering by the Placement Agent of the
Shares.

     (ii) The Company is not an “investment company” or an “affiliated person” of, or
“promoter” or “principal underwriter” for, an “investment company,” as such terms are
defined in the Investment Company Act of 1940, as amended.

     (iii) The Registration Statements have become effective under the Act and, to such
counsel’s knowledge, no stop order suspending the effectiveness of the Registration
Statements has been issued and no proceeding for that purpose has been instituted or is
pending, threatened or contemplated.

     (iv) The Registration Statements and the Prospectuses comply as to form in all material
respects with the requirements of the Act and the Rules and Regulations (other than the
financial statements and schedule contained or incorporated by reference in the Registration
Statements or the Prospectuses, as to which such counsel need express no opinion).

     (v) The documents incorporated by reference in the Prospectuses (other than the
financial statements and schedule contained therein, as to which such counsel need express
no opinion), when they

15

 

were filed with the Commission, complied as to form in all material
respects with the requirements of the Exchange Act and the Exchange Act Rules and
Regulations.

     Such counsel shall also state that (i) such counsel has participated in conferences with the
Placement Agent’s representatives and with representatives of the Company and its accountants
concerning the Registration Statements and the Prospectuses and has considered the matters required
to be stated therein and the statements contained therein, although such counsel has not
independently verified the accuracy, completeness or fairness of such statements, and (ii) that
based upon and subject to the foregoing, nothing has come to the attention of such counsel that
leads such counsel to believe that the Registration Statements, at the time it became effective,
contained an untrue statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, or that the
Prospectuses, at the time they were filed with the Commission pursuant to Rule 424(b) under the Act
or as of the Closing Date, contained an untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading (it being understood that such
counsel is not being requested to and is not required to make any comment in such statement with
respect to the financial statements and other financial information contained in the Registration
Statements or Prospectuses)

     (h) The Placement Agent shall have received an opinion, dated the Closing Date, from Perkins
Coie LLP, patent counsel to the Company, with respect to certain patent matters, which opinions
shall be reasonably satisfactory in all respects to the Placement Agent:

     (i) The Placement Agent shall have received an opinion, dated the Closing Date, from each of
Hewitsons Solicitors and Clifford Chance LLP, counsel to the Company with respect to Semitool
Europe Ltd. and Semitool Japan Inc., respectively, with respect to certain matters relating to such
Subsidiaries, which opinions shall be reasonably satisfactory in all respects to the Placement
Agent:

     (j) The Placement Agent shall have received an opinion, dated the Closing Date, from Fenwick &
West LLP, counsel to the Placement Agent, with respect to the Registration Statements, the
Prospectuses and this Agreement, which opinion shall be satisfactory in all respects to the
Placement Agent.

     (k) Concurrently with the execution and delivery of this Agreement, the Accountants shall have
furnished to the Placement Agent a letter, dated the date of its delivery, addressed to the
Placement Agent and in form and substance satisfactory to the Placement Agent and the Accountants,
confirming that they are independent accountants with respect to the Company and its Subsidiaries
as required by the Act and the Exchange Act and the Rules and Regulations and with respect to
certain financial and other statistical and numerical information contained or incorporated by
reference in the Registration Statements. At the Closing Date, the Accountants shall have
furnished to the Placement Agent a letter, dated the date of its delivery, which shall confirm, on
the basis of a review in accordance with the procedures set forth in the letter from the
Accountants, that nothing has come to their attention during the period from the date of the letter
referred to in the prior sentence to a date (specified in the letter) not more than three days
prior to the Closing Date, which would require any change in their letter dated the date hereof if
it were required to be dated and delivered at the Closing Date.

     (l) At the Closing Date, there shall be furnished to the Placement Agent a certificate, dated
the date of its delivery, signed by each of the Chief Executive Officer and the Chief Financial
Officer of the Company, in form and substance satisfactory to the Placement Agent, to the effect
that:

     (i) Each signer of such certificate has carefully examined the Registration Statements
and the Prospectuses (including any documents filed under the Exchange Act and deemed to be
incorporated by reference into the Prospectuses) and (A) as of the date of such certificate,
such documents are true and
correct in all material respects and do not omit to state a material fact required to
be stated therein or necessary in order to make the statements therein not untrue or
misleading and (B) since the Effective Date no event has occurred as a result of which it is
necessary to amend or supplement the Prospectuses in order to make the statements therein
not untrue or misleading.

     (ii) Each of the representations and warranties of the Company contained in this
Agreement were, when originally made, and are, at the time such certificate is delivered,
true and correct.

16

 

     (iii) Each of the covenants required to be performed by the Company herein on or prior
to the date of such certificate has been duly, timely and fully performed and each condition
herein required to be satisfied or fulfilled on or prior to the date of such certificate has
been duly, timely and fully satisfied or fulfilled.

     (m) On or prior to the Closing Date, the Placement Agent shall have received the executed
agreements referred to in Section 5(o).

     (n) The Shares shall be qualified for sale in such jurisdictions as the Placement Agent may
reasonably request and each such qualification shall be in effect and not subject to any stop order
or other proceeding on the Closing Date.

     (o) Prior to the Closing Date, the Shares shall have been duly authorized for listing on the
NNM upon official notice of issuance.

     (p) At the Closing Date, the Selling Stockholder shall have furnished to the Placement Agent a
certificate stating that the representations, warranties and agreements of the Selling Stockholder
contained herein are true and correct as of the Closing Date and that the Selling Stockholder has
complied with all agreements contained herein to be performed by the Selling Stockholder at or
prior to the Closing Date.

     (q) The Company shall have furnished to the Placement Agent such certificates, in addition to
those specifically mentioned herein, as the Placement Agent may have reasonably requested as to the
accuracy and completeness at the Closing Date of any statement in the Registration Statement or the
Prospectus, as to the accuracy at the Closing Date of the representations and warranties of the
Company herein, as to the performance by the Company of its obligations hereunder, or as to the
fulfillment of the conditions concurrent and precedent to the obligations hereunder of the
Placement Agent.

     9. Indemnification.

     (a) The Company will indemnify and hold harmless the Placement Agent, the directors, officers,
employees and agents of the Placement Agent and each person, if any, who controls the Placement
Agent within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, from and
against any and all losses, claims, liabilities, expenses and damages (including any and all
investigative, legal and other expenses reasonably incurred in connection with, and any amount paid
in settlement of, any action, suit or proceeding or any claim asserted), to which they, or any of
them, may become subject under the Act, the Exchange Act or other federal or state statutory law or
regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or
damages arise out of or are based on any untrue statement or alleged untrue statement of a material
fact contained in any preliminary prospectus, the Registration Statements, the Base Prospectus, any
Prospectus Supplement, the Prospectuses or any amendment or supplement thereto, or any Issuer Free
Writing Prospectus, or the omission or alleged omission to state in such document a material fact
required to be stated in it or necessary to make the statements in it not misleading in the light
of the circumstances in which they were made, or arise out of or are based in whole or in part on
any inaccuracy in the representations and warranties of the Company contained herein or any failure
of the Company to perform its obligations hereunder or under law in connection with the
transactions contemplated hereby; provided, however, that the Company will not be liable to the
extent that such loss, claim, liability, expense or damage arises from the sale of the Shares to
any Investor and is based on an untrue statement or omission or alleged untrue statement or
omission made in reliance on and in conformity with information relating to the Placement Agent
furnished in writing to the Company by the Placement Agent expressly for inclusion in any
preliminary prospectus, the Registration Statements, the Base Prospectus, any Prospectus
Supplement, the Prospectuses, or any Issuer Free Writing Prospectus. The Company acknowledges that
the statements set forth in the last paragraph under the heading “Plan of Distribution” in the
Prospectus Supplement constitute the only information relating to the Placement Agent furnished in
writing to the Company by the Placement Agent expressly for inclusion in any preliminary
prospectus, the Registration Statements, the Base Prospectus, any Prospectus Supplement, the
Prospectuses, or any Issuer Free Writing Prospectus. This indemnity agreement will be in addition
to any liability that the Company might otherwise have.

17

 

     (b) The Selling Stockholder will indemnify and hold harmless the Placement Agent, the
directors, officers, employees and agents of the Placement Agent and each person, if any, who
controls the Placement Agent within the meaning of Section 15 of the Act or Section 20 of the
Exchange Act, from and against any and all losses, claims, liabilities, expenses and damages
(including any and all investigative, legal and other expenses reasonably incurred in connection
with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted),
to which they, or any of them, may become subject under the Act, the Exchange Act or other federal
or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims,
liabilities, expenses or damages arise out of or are based on any untrue statement or alleged
untrue statement of a material fact contained in any preliminary prospectus, the Registration
Statements, the Base Prospectus, any Prospectus Supplement, the Prospectuses or any amendment or
supplement thereto, or any Issuer Free Writing Prospectus, or the omission or alleged omission to
state in such document a material fact required to be stated in it or necessary to make the
statements in it not misleading in the light of the circumstances in which they were made, or arise
out of or are based in whole or in part on any inaccuracy in the representations and warranties of
the Selling Stockholder contained herein or any failure of the Selling Stockholder to perform its
obligations hereunder or under law in connection with the transactions contemplated hereby;
provided, however, that the Selling Stockholder will not be liable to the extent that such loss,
claim, liability, expense or damage arises from the sale of the Shares to any Investor and is based
on an untrue statement or omission or alleged untrue statement or omission made in reliance on and
in conformity with information relating to the Placement Agent furnished in writing to the Company
by the Placement Agent expressly for inclusion in any preliminary prospectus, the Registration
Statements, the Base Prospectus, any Prospectus Supplement, the Prospectuses, or any Issuer Free
Writing Prospectus; provided, further, however, the Selling Stockholder shall not be responsible,
either pursuant to this Section 9 or as a result of any other provision of this Agreement,
including breaches of any representations, warranties or covenants made in this Agreement, or
otherwise in connection with the transactions contemplated hereby, for any losses, expenses,
liabilities or claims, including claims for settlements made, contribution or expense
reimbursement, which in the aggregate exceed the proceeds, after deducting the Fees paid by the
Selling Stockholder, received by the Selling Stockholder from the sale of the Shares by the Selling
Stockholder hereunder. The Selling Stockholder acknowledges that the statements set forth in the
last paragraph under the heading “Plan of Distribution” in the Prospectus Supplement constitute the
only information relating to the Placement Agent furnished in writing to the Company by the
Placement Agent expressly for inclusion in any preliminary prospectus, the Registration Statements,
the Base Prospectus, any Prospectus Supplement, the Prospectuses, or any Issuer Free Writing
Prospectus. This indemnity agreement will be in addition to any liability that the Company might
otherwise have.

     (c) The Placement Agent will indemnify and hold harmless the Company, each director of the
Company, each officer of the Company who signs the Registration Statement, and each person, if any,
who controls the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange
Act, and the Selling Stockholder to the same extent as the foregoing indemnity from the Company to
the Placement Agent, as set forth in Section 9(a), but only insofar as losses, claims, liabilities,
expenses or damages arise out of or are based on any untrue statement or omission or alleged untrue
statement or omission made in reliance on and in conformity with information relating to the
Placement Agent furnished in writing to the Company by the Placement Agent expressly for use in any
preliminary prospectus, the Registration Statements, the Base Prospectus, any Prospectus
Supplement, the Prospectuses, or any Issuer Free Writing Prospectus. The Company and the Selling
Stockholder acknowledge that the statements set forth in the last paragraph under the heading “Plan
of Distribution” in the Prospectus Supplement constitute the only information relating to the
Placement Agent furnished in writing to the Company by the Placement Agent expressly for use in any
preliminary prospectus, the Registration Statements, the Base Prospectus, any Prospectus
Supplement, the Prospectuses, or any Issuer Free Writing Prospectus. This indemnity will be in
addition to any liability that the Placement Agent might otherwise have.

     (d) Any party that proposes to assert the right to be indemnified under this Section 9 shall,
promptly after receipt of notice of commencement of any action against such party in respect of
which a claim is to be made against an indemnifying party or parties under this Section 9, notify
each such indemnifying party in writing of the commencement of such action, enclosing with such
notice a copy of all papers served, but the omission so to notify such indemnifying party will not
relieve it from any liability that it may have to any indemnified party under the foregoing
provisions of this Section 9 unless, and only to the extent that, such omission results in the loss
of substantive rights or defenses by the indemnifying party. If any such action is brought against
any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying
party will be entitled to participate in and, to the extent that it elects by delivering written
notice to the indemnified party promptly after receiving notice

18

 

of the commencement of the action
from the indemnified party, jointly with any other indemnifying party similarly notified, to assume
the defense of the action, with counsel reasonably satisfactory to the indemnified party. After
notice from the indemnifying party to the indemnified party of its election to assume the defense,
the indemnifying party will not be liable to the indemnified party for any legal or other expenses
except as provided below and except for the reasonable costs of investigation incurred by the
indemnified party in connection with the defense. The indemnified party will have the right to
employ its own counsel in any such action, but the fees, expenses and other charges of such counsel
will be at the expense of such indemnified party unless (i) the employment of counsel by the
indemnified party has been authorized in writing by the indemnifying party, (ii) the indemnified
party has reasonably concluded (based on advice of counsel) that there may be legal defenses
available to it or other indemnified parties that are different from or in addition to those
available to the indemnifying party, (iii) a conflict or potential conflict exists (based on advice
of counsel to the indemnified party) between the indemnified party and the indemnifying party (in
which case the indemnifying party will not have the right to direct the defense of such action on
behalf of the indemnified party) or (iv) the indemnifying party has not in fact employed counsel
reasonably satisfactory to the indemnified party to assume the defense of such action within a
reasonable time after receiving notice of the commencement of the action, in each of which cases
the reasonable fees, disbursements and other charges of counsel will be at the expense of the
indemnifying party or parties. It is understood that the indemnifying party or parties shall not,
in connection with any proceeding or related proceedings in the same jurisdiction, be liable for
the reasonable fees, disbursements and other charges of more than one separate firm admitted to
practice in such jurisdiction at any one time for all such indemnified party or parties. All such
fees, disbursements and other charges will be reimbursed by the indemnifying party promptly as they
are incurred. No indemnifying party shall, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened action in respect of which any
indemnified party is or could have been a party and indemnity could have been sought hereunder by
such indemnified party unless such settlement (i) includes an unconditional release of such
indemnified party from all liability on any claims that are the subject matter of such action and
(ii) does not include a statement as to, or an admission of, fault, culpability or a failure to act
by or on behalf of an indemnified party. An indemnifying party will not be liable for any
settlement of any action or claim effected without its written consent (which consent will not be
unreasonably withheld or delayed).

     (e) If the indemnification provided for in this Section 9 is applicable in accordance with its
terms but for any reason is held to be unavailable to or insufficient to hold harmless an
indemnified party under paragraphs (a), (b), (c) and (d) of this Section 9 in respect of any
losses, claims, liabilities, expenses and damages referred to therein, then each applicable
indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount
paid or payable (including any investigative, legal and other expenses reasonably incurred in
connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim
asserted, but after deducting any contribution received by the Company or the Selling Stockholder
from persons other than the Placement Agent, such as persons who control the Company within the
meaning of the Act, officers of the Company who signed the Registration Statements and directors of
the Company, who also may be liable for contribution) by such indemnified party as a result of such
losses, claims, liabilities, expenses and damages in such proportion as shall be appropriate to
reflect the relative benefits received by the Company and the Selling Stockholder, on the one hand,
and the Placement Agent, on the other hand. The relative benefits received by the Company and the
Selling Stockholder, on the one hand, and the Placement Agent, on the other hand, shall be deemed
to be in the same proportion as the total net proceeds from the offering (before deducting
expenses) received by the Company and the Selling Stockholder bear to the total Fee received by the
Placement Agent pursuant to this Agreement. If, but only if, the allocation provided by the
foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made
in such proportion as is appropriate to reflect not only the relative benefits referred to in the
foregoing sentence but also the relative fault of the Company and the Selling Stockholder, on the
one hand, and the Placement Agent, on the other hand, with respect to the statements or omissions
that resulted in such loss, claim, liability, expense or damage,
or action in respect thereof, as well as any other relevant equitable considerations with
respect to such offering. Such relative fault shall be determined by reference to whether the
untrue or alleged untrue statement of a material fact or omission or alleged omission to state a
material fact relates to information supplied by the Company, the Selling Stockholder or the
Placement Agent, the intent of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such statement or omission. The Company, the Selling Stockholder
and the Placement Agent agree that it would not be just and equitable if contributions pursuant to
this Section
9(e) were to be determined by pro rata allocation or by any other method of allocation
that does not take into account the equitable considerations referred to herein. The amount paid
or payable by an indemnified party as a result of the loss claim, liability, expense or damage, or
action in respect thereof, referred to above in this Section

19

 

9(e) shall be deemed to include, for
purposes of this Section 9(e), any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this Section 9(e), in no case shall the Placement Agent be required to contribute any
amount in excess of the Fee received by the Placement Agent pursuant to this Agreement. No person
found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) will
be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section 9(e), any person who controls a party to this
Agreement within the meaning of the Act will have the same rights to contribution as that party,
and each officer of the Company who signed the Registration Statements will have the same rights to
contribution as the Company, subject in each case to the provisions hereof. Any party entitled to
contribution, promptly after receipt of notice of commencement of any action against any such party
in respect of which a claim for contribution may be made under this Section 9(e), will notify any
such party or parties from whom contribution may be sought, but the omission so to notify will not
relieve the party or parties from whom contribution may be sought from any other obligation it or
they may have under this Section 9(e). No party will be liable for contribution with respect to
any action or claim settled without its written consent (which consent will not be unreasonably
withheld).

     (f) The indemnity and contribution agreements contained in this Section 9 and the
representations and warranties of the Company and the Selling Stockholder contained in this
Agreement shall remain operative and in full force and effect regardless of (i) any investigation
made by or on behalf of the Placement Agent, (ii) acceptance by the Investors of any of the Shares
and payment therefor, or (iii) any termination of this Agreement.

     10. Reimbursement of Certain Expenses. In addition to its other obligations under Section 9
of this Agreement, the Company hereby agrees to reimburse the Placement Agent on a quarterly basis
for all reasonable legal and other expenses incurred in connection with investigating or defending
any claim, action, investigation, inquiry or other proceeding arising out of or based upon, in
whole or in part, any statement or omission or alleged statement or omission, or any inaccuracy in
the representations and warranties of the Company contained herein or failure of the Company to
perform its or their respective obligations hereunder or under law, all as described in Section 9,
notwithstanding the absence of a judicial determination as to the propriety and enforceability of
the obligations under this Section 9 and the possibility that such payment might later be held to
be improper; provided, however, that, to the extent any such payment is ultimately held to be
improper, the persons receiving such payments shall promptly refund them. In addition to its other
obligations under Section 9 of this Agreement, the Selling Stockholder hereby agrees to reimburse
the Placement Agent on a quarterly basis for all reasonable legal and other expenses incurred in
connection with investigating or defending any claim, action, investigation, inquiry or other
proceeding arising out of or based upon, in whole or in part, any statement or omission or alleged
statement or omission, or any inaccuracy in the representations and warranties of the Selling
Stockholder contained herein or failure of the Selling Stockholder to perform its or their
respective obligations hereunder or under law, all as described in Section 9, notwithstanding the
absence of a judicial determination as to the propriety and enforceability of the obligations under
this Section 9 and the possibility that such payment might later be held to be improper; provided,
however, that, to the extent any such payment is ultimately held to be improper, the persons
receiving such payments shall promptly refund them.

     11. Termination. The obligations of the Placement Agent under this Agreement may be
terminated at any time on or prior to the Closing Date, by notice to the Company and the Selling
Stockholder from the Placement Agent, without liability on the part of the Placement Agent to the
Company or the Selling Stockholder if in the sole judgment of the
Placement Agent, (i) trading in any of the equity securities of the Company shall have been
suspended or limited by the Commission or by The Nasdaq Stock Market, (ii) trading in securities
generally on the New York Stock Exchange or The Nasdaq Stock Market shall have been suspended or
limited or minimum or maximum prices shall have been generally established on such exchange, or
additional material governmental restrictions, not in force on the date of this Agreement, shall
have been imposed upon trading in securities generally by such exchange, by order of the Commission
or any court or other governmental authority, or by The Nasdaq Stock Market, (iii) a general
banking moratorium shall have been declared by federal, New York State or California State
authorities or any material disruption of the securities settlement or clearance services in the
United States shall have occurred, or (iv) any material adverse change in the financial or
securities markets in the United States or in political, financial or economic conditions in the
United States, any outbreak or material escalation of hostilities involving the United States, a
declaration of a national emergency or war by the United States, or other calamity or crisis,
either within or outside the United States, shall have occurred, the effect of which is such as to
make it, in the sole judgment of the Placement Agent, impracticable or inadvisable to proceed with
completion of the placement of the Shares.

20

 

     If this Agreement is terminated pursuant to Section 11 hereof, neither the Company nor the
Selling Stockholder shall be under any liability to the Placement Agent except as provided in
Sections 5(j), 9 and 10 hereof; but, if for any other reason this Agreement is terminated or the
placement of the Shares is not consummated or if for any reason the Company or the Selling
Stockholder shall be unable to perform their obligations hereunder, the Company will reimburse the
Placement Agent for all out-of-pocket expenses (including the fees, disbursements and other charges
of counsel to the Placement Agent) incurred by the Placement Agent in connection with this
Agreement or the offering contemplated hereunder.

     12. Notices. Notice given pursuant to any of the provisions of this Agreement shall be in
writing and, unless otherwise specified, shall be mailed or delivered (a) if to the Company, at the
office of the Company, 655 West Reserve Drive, Kalispell, MT 59901, Attention: Chief Executive
Officer, with a copy to Justin L. Bastian, Esq., Morrison & Foerster LLP, 755 Page Mill Road, Palo
Alto, CA 94304, (b) if to the Selling Stockholder, at the office of the Company, 655 West Reserve
Drive, Kalispell, MT 59901, Attention: Raymon F. Thompson, with a copy to Justin L. Bastian, Esq.,
Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304 or (c) if to the Placement Agent,
at the offices of (i) Needham & Company, LLC, 445 Park Avenue, New York, New York 10022, Attention:
Corporate Finance Department, with a copy to Laird H. Simons, III, Esq., Fenwick & West LLP, 801
California Street, Mountain View, CA 94041. Any such notice shall be effective only upon receipt.
Any notice under Section 12 may be made by telecopier or telephone, but if so made shall be
subsequently confirmed in writing.

     13. No Fiduciary Relationship. Notwithstanding any preexisting relationship, advisory or
otherwise, between the parties or any oral representations or assurances previously or subsequently
made by the Placement Agent, the Company and the Selling Stockholder acknowledge and agree that (i)
the purchase and sale of the Shares pursuant to this Agreement (including the determination of the
terms of the offering of the Shares) is an arms’-length commercial transaction between the Company,
the Selling Stockholder and the several Investors, (ii) the Placement Agent has not assumed an
advisory or fiduciary responsibility in favor of the Company or the Selling Stockholder with
respect to the offering contemplated hereby or the process leading thereto (irrespective of whether
the Placement Agent has advised or is currently advising the Company or the Selling Stockholder on
other matters) or any other obligation to the Company or the Selling Stockholder except the
obligations expressly set forth in this Agreement, (iii) the Placement Agent and its affiliates may
be engaged in a broad range of transactions that involve interests that differ from those of the
Company and the Selling Stockholder and have no obligation to disclose or account to the Company or
the Selling Stockholder for any of such differing interests, and (iv) the Company and the Selling
Stockholder have consulted their own legal, tax, accounting and financial advisors to the extent
they deemed appropriate. The Company and the Selling Stockholder hereby agree that they will not
claim that the Placement Agent has rendered advisory services of any nature or respect, or owes a
fiduciary or similar duty to the Company and the Selling Stockholder, in connection with such
transaction or the process leading thereto.

     14. Miscellaneous.

     This Agreement has been and is made solely for the benefit of the Placement Agent, the
Company, the Selling Stockholder and the controlling persons, directors and officers referred to in
Section 9, and their respective successors and assigns, and no other person shall acquire or have
any right under or by virtue of this Agreement.

     This Agreement supersedes all prior agreements and understandings (whether written or oral)
between the Company, the Selling Stockholder and the Placement Agent, or any of them, with respect
to the subject matter hereof.

     This Agreement shall be governed by and construed in accordance with the laws of the State of
New York applicable to contracts made and to be performed entirely within such State.

     This Agreement may be signed in two or more counterparts with the same effect as if the
signatures thereto and hereto were upon the same instrument.

     In case any provision in this Agreement shall be invalid, illegal or unenforceable, the
validity, legality and enforceability of the remaining provisions shall not in any way be affected
or impaired thereby.

21

 

     Each of the Company, the Selling Stockholder and the Placement Agent hereby waives any right
it may have to a trial by jury in respect of any claim based upon or arising out of this Agreement
or the transactions contemplated hereby.

[rest of page intentionally left blank]

22

 

     Please confirm that the foregoing correctly sets forth the agreement among the Company, the
Selling Stockholder and the Placement Agent.

	 	 	 	 	 
	 	Very truly yours,

Semitool, Inc.

 	 
	 	By:  	/s/ Larry A. Viano
 	 
	 	 	Name: Larry A. Viano	 
	 	 	Title: VP-Finance, CFO	 
	 

	 	 	 	 	 
	 	Selling Stockholder

 	 	 	 	 	 	 	 	 	 	 	 
	 	/s/ Raymon F. Thompson
 	 
	 	Raymon F. Thompson 	 
	 	 	 
	 

Confirmed as of the date first

above mentioned:

	 	 	 	 	 
	Needham & Company, LLC	 	 
	 
	 	 	 	 
	By:

	 	/s/ Chad W. Keck
	 	 
	 

	 	 	 	 
	 

	 	Title: Managing Director	 	 

 

 

EXHIBIT A

FORM OF PURCHASE AGREEMENT

Semitool, Inc.

655 West Reserve Drive

Kalispell, Montana 59901

Raymon F. Thompson

c/o Semitool, Inc.

655 West Reserve Drive

Kalispell, Montana 59901

Ladies and Gentlemen:

     The undersigned, [___] (the “Investor”), hereby confirms and agrees with you
as follows:

     1. This Purchase Agreement (the “Agreement”) is made as of December 15, 2005 among Semitool,
Inc., a Montana corporation (the “Company”), Raymon F. Thompson (the “Selling Stockholder”) and the
Investor.

     2. As of the Closing (as defined below) and subject to the terms and conditions hereof, the
Company, the Selling Stockholder and the Investor agree that the Investor will purchase from the
Company and the Company will issue and sell to the Investor [___] shares of common stock,
no par value per share, of the Company (“Common Stock”), and the Investor will purchase from the
Selling Stockholder and the Selling Stockholder will sell to the Investor [___] shares of
Common Stock (collectively with the shares of common stock to be sold by the Company to the
Investor, the “Shares”), for a purchase price of $9.85 per share, or an aggregate purchase price of
$[___]. The Investor acknowledges that the offering of the Shares is not a firm
commitment underwriting and that there is no minimum offering amount.

     3. The completion of the purchase and sale of the Shares shall occur at a closing (the
“Closing”) which is expected to occur on or about December 21, 2005. After the execution of this
Agreement by the Investor, the Investor shall remit to the Company and to the Selling Stockholder,
by wire transfer to the account designated by the Company, the Selling Stockholder and the
Placement Agent (as defined below) in this Agreement, the amount of funds equal to the aggregate
purchase price of the Shares. Unless otherwise requested by the Investor and agreed to by the
Company and the Selling Stockholder, the Shares purchased by the Investor will be delivered by
electronic book-entry at The Depository Trust Company (“DTC”), registered in the Investor’s name
and address as set forth below, and will be released by Registrar and Transfer Company, the
Company’s transfer agent (the “Transfer Agent”), to the Investor at the Closing. After the
execution of this Agreement by the Investor, the Investor shall direct the broker-dealer at which
the account or accounts to be credited with the Shares are maintained to set up a
deposit/withdrawal at custodian (“DWAC”) instructing the Transfer Agent to credit such account or
accounts with the Shares.

     4. The offering and sale of the Shares are being made pursuant to the Registration Statements
and Prospectuses (as such terms are defined below). The Investor acknowledges that the Company and
the Selling Stockholder intend to enter into purchase agreements in substantially the same form as
this Agreement with certain other investors and intend to offer and sell (the “Offering”) up to an
aggregate of 5,000,000 shares of Common Stock pursuant to the Registration Statements and
Prospectuses.

     5. The Company has filed or shall file with the Securities and Exchange Commission (the
“Commission”) a prospectus (the “Base Prospectus”) and prospectus supplement (collectively the
“Company Prospectus”) with respect to the registration statement (File No. 333-39492) reflecting
the offering of the Shares by the Company, including all amendments thereto, the exhibits and any
schedules thereto, the documents otherwise deemed to be a part thereof or included therein by the
rules and regulations of the Commission (the “Rules and Regulations”), and

A-1

 

any registration statement relating to the offering contemplated by this Agreement and filed
pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Company Registration
Statement”), in conformity with the Securities Act of 1933, as amended (the “Securities Act”),
including Rule 424(b) thereunder. The Selling Stockholder has filed with the Commission a
prospectus (the “Selling Stockholder Prospectus,” and, together with the Company Prospectus, the
“Prospectuses”) and registration statement (File No. 333-112964) reflecting the offering of the
Shares by the Selling Stockholder, including all amendments thereto, the exhibits and any schedules
thereto, the documents otherwise deemed to be a part thereof or included therein by the Rules and
Regulations, and any registration statement relating to the offering contemplated by this Agreement
and filed pursuant to Rule 462(b) under the Rules and Regulations (collectively, the “Selling
Stockholder Registration Statement,” and, together with the Company Registration Statement, the
“Registration Statements”), in conformity with the Securities Act, including Rule 424(b)
thereunder. The Investor hereby confirms that it had full access to the Base Prospectus and the
Selling Stockholder Prospectus, and the Company’s periodic reports and other information
incorporated by reference therein, and was fully able to read, review, download and print such
materials.

     6. The Company and the Selling Stockholder have entered into a Placement Agency Agreement,
dated December 15, 2005 (the “Placement Agency Agreement”), with Needham & Company, LLC (the
“Placement Agent”), which will act as the Company’s and the Selling Stockholder’s placement agent
with respect to the Offering and receive a fee in connection with the sale of the Shares. A copy of
the Placement Agency Agreement is available upon request.

     7. The Company’s obligations to issue and sell Shares to the Investor, and the Selling
Stockholders obligation to sell Shares to the Investor, shall be subject to the accuracy of the
representations and warranties made by the Investor and the fulfillment of those undertakings of
the Investor to be fulfilled prior to the Closing.

     The Investor’s obligation to purchase the Shares shall be subject to the condition that the
Placement Agent shall not have (a) terminated the Placement Agency Agreement pursuant to the terms
thereof or (b) determined that the conditions to closing in the Placement Agency Agreement have not
been satisfied.

     8. The Company hereby makes the following representations, warranties and covenants to the
Investor:

          (a) The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by this Agreement and otherwise to carry out its
obligations hereunder. The execution and delivery of this Agreement by the Company and the
consummation by it of the transactions contemplated hereunder have been duly authorized by all
necessary action on the part of the Company. This Agreement has been duly executed by the Company
and, when delivered in accordance with the terms hereof, will constitute the valid and binding
obligation of the Investor enforceable against the Company in accordance with its terms, except as
may be limited by any bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or
other similar laws affecting the enforcement of creditors’ rights generally or by general
principles of equity.

          (b) The Company shall (i) before the opening of trading on the Nasdaq National Market on the
next trading day after the date hereof, issue a press release, disclosing all material aspects of
the transactions contemplated hereby and (ii) make such other filings and notices in the manner and
time required by the Commission with the respect to the transaction contemplated hereby. The
Company shall not identify the Investor by name in any press release or public filing, or otherwise
publicly disclose the Investor’s name, without the Investor’s prior, written consent, unless
required by law or the rules and regulations of any self-regulatory organization which the Company
or its securities are subject.

     9. The Selling Stockholder hereby makes the following representations, warranties and
covenants to the Investor:

          (a) The Selling Stockholder has, and immediately prior to the Closing the Selling Stockholder
will have, good and valid title to the Shares to be sold by the Selling Stockholder hereunder, free
and clear of all liens, encumbrances, equities or claims; and upon delivery of such Shares and
payment therefor by the Investor, good and valid title to such shares, free and clear of all liens,
encumbrances, equities or claims, will pass to the Investor.

A-2

 

          (b) The Selling Stockholder has full power and authority to enter into and to consummate the
transactions contemplated by this Agreement and otherwise to carry out his obligations hereunder.
This Agreement has been duly executed by the Selling Stockholder and, when delivered in accordance
with the terms hereof, will constitute the valid and binding obligation of the Investor enforceable
against the Selling Stockholder in accordance with its terms, except as may be limited by any
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws
affecting the enforcement of creditors’ rights generally or by general principles of equity.

          (c) The Selling Stockholder is not prompted to sell Shares by any material information
concerning the Company which is not set forth in, or incorporated by reference into, the
Prospectuses or the Registration Statements.

     10. The Investor hereby makes the following representations, warranties and covenants to the
Company and the Selling Stockholder:

          (a) The Investor represents that it has received or had full access to the Base Prospectus and
the Selling Stockholder Prospectus, as well as the Company’s periodic reports and other information
incorporated by reference therein, prior to or in connection with its receipt of this Agreement.
The Investor further represents that it is knowledgeable, sophisticated and experienced in making,
and is qualified to make, decisions with respect to investments in shares representing an
investment decision like that involved in the purchase of the Shares. The Investor further
represents that it has read and understands the contents of this Agreement and that the Investor
understands and agrees to the form of transaction relating to the sale of Shares contemplated by
this Agreement.

          (b) From and after obtaining knowledge of the sale of the Shares contemplated hereby, such
Investor has not taken, and prior to the public announcement of the transaction such Investor shall
not take, any action that has caused or will cause such Investor to have, directly or indirectly,
sold or agreed to sell any Common Stock, effected any short sale, whether or not against the box,
established any “put equivalent position” (as defined in Rule 16a-1(h) under the Securities
Exchange Act of 1934, as amended) with respect to the Common Stock, granted any other right
(including, without limitation, any put or call option) with respect to the Common Stock or with
respect to any security that includes, relates to or derives any significant part of its value from
the Common Stock, whether or not, directly or indirectly, in order to hedge its position in the
Shares.

          (c) The Investor shall not issue any press release or make any other public announcement
relating to this Agreement unless (i) the content thereof is mutually agreed to by the Company, the
Selling Stockholder and the Investor or (ii) the Investor is advised by its counsel that such press
release or public announcement is required by law.

          (d) The Investor has the requisite power and authority to enter into and to consummate the
transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder.
The execution and delivery of this Agreement by the Investor and the consummation by it of the
transactions contemplated hereunder have been duly authorized by all necessary action on the part
of the Investor. This Agreement has been duly executed by the Investor and, when delivered in
accordance with the terms hereof, will constitute the valid and binding obligation of the Investor
enforceable against the Investor in accordance with its terms, except as may be limited by any
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws
affecting the enforcement of creditors’ rights generally or by general principles of equity.

          (e) The Investor understands that nothing in this Agreement or any other materials presented
to the Investor in connection with the purchase or sale of the Shares constitutes legal, tax or
investment advice. The Investor has consulted such legal, tax or investment advisors as it, in its
sole discretion, deems necessary or appropriate in connection with its purchase of the Shares.

          (f) The Investor represents that[, except as set forth below,] (a) it has had no position,
office or other material relationship within the past three years with the Company or persons known
to it to be affiliates of the Company, (b) neither it, nor any group of which it is a member or to
which it is related, beneficially owns (including the right to acquire or vote) any securities of
the Company, and (c) it is not a, and it has no direct or indirect affiliation or association with
any, National Association of Securities Dealers, Inc. member as of the date hereof. [Exceptions:]

A-3

 

     10. Notwithstanding any investigation made by any party to this Agreement, all covenants,
agreements, representations and warranties made by the Company, the Selling Stockholder and the
Investor herein shall survive the execution of this Agreement, the delivery to such Investor of the
Shares being purchased and the payment therefor.

     11. This Agreement shall be governed by, and construed in accordance with, the internal laws
of the State of New York, without giving effect to the principles of conflicts of law.

     12. This Agreement may be executed in two or more counterparts, each of which shall constitute
an original, but all of which, when taken together, shall constitute but one instrument, and shall
become effective when one or more counterparts have been signed by each party hereto and delivered
to the other parties.

[Remainder of page intentionally left blank.]

A-4

 

     Please confirm that the foregoing correctly sets forth the agreement between us by signing in
the space provided below for that purpose.

	 	 	 
	 

	 	Name of Investor:
	 

	 	 

	 
	 	 
	 

	 	By:
	 

	 	 

	 
	 	 
	 

	 	Print Name:
	 

	 	 

	 
	 	 
	 

	 	Title:
	 

	 	 

	 
	 	 
	 

	 	Address:
	 

	 	 

	 
	 	 
	 

	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	 

	 	Tax ID No.:
	 

	 	 

	 
	 	 
	 

	 	Contact Name:
	 

	 	 

	 
	 	 
	 

	 	Telephone:
	 

	 	 

	 
	 	 
	 

	 	Name in which book-entry should be made (if different):
	 
	 	 
	 

	 	 

	 	 	 
	AGREED AND ACCEPTED:
	 	 
	 
	 	 
	Semitool, Inc.
	 	 
	a Montana corporation
	 	 
	 
	 	 
	By:

	 	 
	 
	 	 
	Name:
	 	 
	Title:
	 	 
	 
	 	 
	Selling Stockholder
	 	 
	 
	 	 
	 

Raymon F. Thompson

	 	 

The Company, the Selling Stockholder and the Placement Agent have established an account pursuant
to the terms of an Escrow Agreement and hereby direct that the purchase price for the Shares of
common stock being sold by the Company to the Investor pursuant to this Agreement be wired to the
following account:

	 	 	 
	 

	 	Bank:
	 

	 	 

	 

	 	ABA#
	 

	 	 

	 

	 	Credit to:
	 

	 	 

	 

	 	Account No.
	 

	 	 

	 

	 	Re: Semitool, Inc.

A-5

 

EXHIBIT B

FORM OF LOCK-UP AGREEMENT

Needham & Company, LLC

445 Park Avenue

New York, New York 10022

Ladies and Gentlemen:

     The undersigned is a holder of securities of Semitool, Inc., a Montana corporation (the
“Company”), and wishes to facilitate the public offering of shares of the Common Stock (the “Common
Stock”) of the Company (the “Offering”). The undersigned recognizes that such Offering will be of
benefit to the undersigned.

     In consideration of the foregoing and in order to induce you to act as placement agent in
connection with the Offering, the undersigned hereby agrees that, during the period commencing as
of the date hereof and ending on the date that is ninety (90) days after the date of the final
Prospectus Supplement relating to the Offering (the “Lock-Up Period”), the undersigned will not,
without the prior written approval of Needham & Company, LLC, directly or indirectly, (1) offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or
dispose of any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause (1) or (2) above is to be settled by delivery of
Common Stock or such other securities, in cash or otherwise. Notwithstanding the foregoing, and
subject to the conditions below, the undersigned may transfer the lock-up securities without the
prior written consent of Needham & Company, Inc. in connection with transfers as a bona fide gift
or gifts, or to any trust for the direct or indirect benefit of the undersigned or the immediate
family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean
any relationship by blood, marriage or adoption, not more remote than first cousin), provided that
prior to such transfer a signed lock-up agreement for the balance of the Lock-Up Period from each
donee, trustee, distributee, or transferee, as the case may be, is received by Needham & Company,
Inc., and any such transfer shall not involve a disposition for value. Furthermore, the
undersigned may sell shares of Common Stock of the Company purchased by the undersigned on the open
market following the Offering. If (a) during the last 17 days of the Lock-Up Period the Company
issues an earnings release or material news or a material event relating to the Company occurs or
(b) prior to the expiration of the Lock-Up Period, the Company announces that it will release
earnings results during the 16-day period beginning on the last day of the Lock-Up Period, the
restrictions imposed by this Agreement shall continue to apply until the expiration of the 18-day
period beginning on the issuance of the earnings release or the occurrence of the material news or
material event. In addition, the undersigned agrees that, without the prior written consent of
Needham & Company, LLC, the undersigned will not, during the Lock-Up Period, make any demand for or
exercise any right with respect to, the registration of any shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock. The undersigned confirms that
he, she or it understands that you, as placement agent, and the Company will rely upon the
representations set forth in this Agreement in proceeding with the Offering. The undersigned
further confirms that the agreements of the undersigned are irrevocable and shall be binding upon
the undersigned’s heirs, legal representatives, successors and assigns. The undersigned agrees and
consents to the entry of stop transfer instructions with the Company’s transfer agent against the
transfer of securities held by the undersigned except in compliance with this Agreement. learn

	 	 	 
	 

	 	Very truly yours,
	 
	 	 
	 

	 	 
	 

	 	(Name)

 

 

	 	 	 	 	 
	 

	 	 

(Address)
	 	 

 

 

SCHEDULE I

PERMITTED FREE WRITING PROSPECTUSES

[None]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]